Hello I'm Raiyyan Tahsan
Brand Model and Executive

TC(1377).(23).Urology Department Case No (25):-Nocturia with Suspected Lower Urinary Tract Dysfunction (OAB vs UTI), Bilateral Shoulder Pain and Low Back Pain; Inflammatory Arthritis to Be Excluded (1Prescription+0Report+0Image)(0907)

prescription attached:-

đŸŠē LIPU MED — FULL CLINICAL PRESCRIPTION REVIEW & DIAGNOSTIC ASSESSMENT

āĻŦāĻžāĻ‚āϞāĻž āϰ⧋āĻ—āύāĻŋāĻ°ā§āĻŖāϝāĻŧ: āϰāĻžāϤ⧇ āĻŦāĻžāϰāĻŦāĻžāϰ āĻĒā§āϰāĻ¸ā§āϰāĻžāĻŦ āĻšāĻ“āϝāĻŧāĻžâ€”āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻŽā§‚āĻ¤ā§āϰāĻĨāϞāĻŋāϰ āĻ•āĻžāĻ°ā§āϝāĻ•āĻžāϰāĻŋāϤāĻžāϜāύāĻŋāϤ āϏāĻŽāĻ¸ā§āϝāĻž āĻ…āĻĨāĻŦāĻž āĻŽā§‚āĻ¤ā§āϰāύāĻžāϞ⧀āϰ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ; āωāĻ­āϝāĻŧ āĻ•āĻžāρāϧ āĻ“ āϕ⧋āĻŽāϰ⧇ āĻŦā§āϝāĻĨāĻžāĨ¤ āĻĒā§āϰāĻĻāĻžāĻšāϜāύāĻŋāϤ āĻŦāĻžāϤāϰ⧋āϗ⧇āϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻžāĻ“ āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ•āϰ⧇ āĻĻ⧇āĻ–āϤ⧇ āĻšāĻŦ⧇āĨ¤

Clinical status: Provisional Working Assessment — āϰ⧋āĻ—ā§€āϰ āωāĻĒāϏāĻ°ā§āĻ— āĻ“ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύāĻ­āĻŋāĻ¤ā§āϤāĻŋāĻ• āĻĒā§āϰāĻžāĻĨāĻŽāĻŋāĻ• āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ; āύāĻŋāĻļā§āϚāĻŋāϤ āϰ⧋āĻ—āύāĻŋāĻ°ā§āĻŖāϝāĻŧ āύāϝāĻŧāĨ¤

Patient: Mrs. Minoty Roy
Age: 85 years
Prescription Date: Saturday, 10 October 2026
Prescribing Physician: Dr. Torequl Islam Tonmoy
Review Date: Friday, 16 October 2026

Department: Urology — with Rheumatology and Geriatric Medicine considerations.

Website verification: Raiyyan Tahsan Medical Blog Archive āĻāĻŦāĻ‚ Urology Case Archive āϝāĻžāϚāĻžāχ āĻ•āϰāĻž āĻšāϝāĻŧ⧇āϛ⧇āĨ¤ āϏāĻ°ā§āĻŦāĻļ⧇āώ āĻĻ⧃āĻļā§āϝāĻŽāĻžāύ Total Case 1376, Urology Department Code 23 āĻāĻŦāĻ‚ Urology Case No 24āĨ¤ āϏ⧇āχ āĻ…āύ⧁āϝāĻžāϝāĻŧā§€ āĻāχ āύāϤ⧁āύ, āĻāĻ–āύ⧋ āĻ…āĻĒā§āϰāĻ•āĻžāĻļāĻŋāϤ āύāĻŋāĻŦāĻ¨ā§āϧ⧇āϰ āĻĒā§āϰāĻ¸ā§āϤāĻžāĻŦāĻŋāϤ āύāĻŽā§āĻŦāϰ TC(1377).(23), Case No (25)āĨ¤ āĻĒā§āϰāĻ•āĻžāĻļ⧇āϰ āφāϗ⧇ āĻĒ⧁āύāϰāĻžāϝāĻŧ āϝāĻžāϚāĻžāχ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Overall diagnostic confidence: 0.56/1.00 — Moderate–low. āĻ•āĻžāϰāĻŖ āϰ⧋āĻ—ā§€āϰ āĻŦāĻŋāĻ¸ā§āϤāĻžāϰāĻŋāϤ āχāϤāĻŋāĻšāĻžāϏ, āĻļāĻžāϰ⧀āϰāĻŋāĻ• āĻĒāϰ⧀āĻ•ā§āώāĻž āĻāĻŦāĻ‚ āύāĻŋāĻ°ā§āĻĻ⧇āĻļāĻŋāϤ āĻĒāϰ⧀āĻ•ā§āώāĻžāϗ⧁āϞ⧋āϰ āĻĢāϞāĻžāĻĢāϞ āĻĒāĻžāĻ“āϝāĻŧāĻž āϝāĻžāϝāĻŧāύāĻŋāĨ¤

Important Clinical Safety Alert: ā§Žā§Ģ āĻŦāĻ›āϰ āĻŦāϝāĻŧāϏ⧀ āĻāχ āϰ⧋āĻ—ā§€āϰ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ Tofacitinib, Sulindac, Nitrofurantoin, Mirogabalin āĻāĻŦāĻ‚ āφāϰāĻ“ āĻ•āϝāĻŧ⧇āĻ•āϟāĻŋ āĻ“āώ⧁āϧ āϰāϝāĻŧ⧇āϛ⧇āĨ¤ āĻŦāĻŋāĻļ⧇āώ āĻ•āϰ⧇ Brofex TS-āĻāϰ āϞāĻŋāĻ–āĻŋāϤ āĻĄā§‹āϜ MedEx-āĻāϰ āϏāĻ°ā§āĻŦā§‹āĻšā§āϚ āĻĻ⧈āύāĻŋāĻ• āĻĄā§‹āĻœā§‡āϰ āĻŦ⧇āĻļāĻŋ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤ āĻ“āώ⧁āϧāϗ⧁āϞ⧋āϰ āύāĻŋāϰāĻžāĻĒāĻ¤ā§āϤāĻž, āĻ•āĻŋāĻĄāύāĻŋāϰ āĻ•āĻžāĻ°ā§āϝāĻ•āĻžāϰāĻŋāϤāĻž āĻāĻŦāĻ‚ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻĒāĻžāϰāĻ¸ā§āĻĒāϰāĻŋāĻ• āĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋāϝāĻŧāĻž āĻĻā§āϰ⧁āϤ prescribing doctor āĻŦāĻž clinical pharmacist āĻĻāĻŋāϝāĻŧ⧇ āĻĒ⧁āύāσāϝāĻžāϚāĻžāχ āĻ•āϰāĻž āĻĒā§āϰāϝāĻŧā§‹āϜāύāĨ¤ āĻāχ āĻĒāĻ°ā§āϝāĻžāϞ⧋āϚāύāĻž āϕ⧋āύ⧋ āĻ“āώ⧁āϧ āύāĻŋāĻœā§‡ āĻĨ⧇āϕ⧇ āĻļ⧁āϰ⧁ āĻŦāĻž āĻŦāĻ¨ā§āϧ āĻ•āϰāĻžāϰ āύāĻŋāĻ°ā§āĻĻ⧇āĻļ āύāϝāĻŧāĨ¤


1. Patient Information — āϰ⧋āĻ—ā§€āϰ āĻĒāϰāĻŋāϚāĻŋāϤāĻŋ

Clinical Parameter Prescription Findings āĻŦāĻžāĻ‚āϞāĻž āĻŦā§āϝāĻžāĻ–ā§āϝāĻž Confidence
Patient Name Mrs. Minoty Roy āĻŽāĻŋāϏ⧇āϏ āĻŽāĻŋāύāϤāĻŋ āϰāĻžāϝāĻŧ 0.98
Age 85 Years āĻŦāϝāĻŧāϏ ā§Žā§Ģ āĻŦāĻ›āϰ 0.99
Sex Female āύāĻžāϰ⧀ 0.99
Prescription Date 10-10-2026 ā§§ā§Ļ āĻ…āĻ•ā§āĻŸā§‹āĻŦāϰ ⧍ā§Ļ⧍ā§Ŧ 0.99
Blood Pressure 110/70 mmHg āϰāĻ•ā§āϤāϚāĻžāĻĒ ā§§ā§§ā§Ļ/ā§­ā§Ļ 0.99
Pulse 96 bpm āĻĒā§āϰāϤāĻŋ āĻŽāĻŋāύāĻŋāĻŸā§‡ āĻšā§ƒāĻĻāĻ¸ā§āĻĒāĻ¨ā§āĻĻāύ ⧝ā§Ŧ 0.98
SpO₂ 99% āϰāĻ•ā§āϤ⧇ āĻ…āĻ•ā§āϏāĻŋāĻœā§‡āύ āĻ¸ā§āϝāĻžāϚ⧁āϰ⧇āĻļāύ ⧝⧝% 0.99
Temperature Not documented āĻļāϰ⧀āϰ⧇āϰ āϤāĻžāĻĒāĻŽāĻžāĻ¤ā§āϰāĻž āϞ⧇āĻ–āĻž āύ⧇āχ 0.99
Weight Not documented āĻ“āϜāύ āϞ⧇āĻ–āĻž āύ⧇āχ 0.99
Drug Allergy Not documented āĻ“āώ⧁āϧ⧇ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϰ āχāϤāĻŋāĻšāĻžāϏ āύ⧇āĻ‡â€”āĻāĻŽāύ āϤāĻĨā§āϝ āĻĻ⧇āĻ“āϝāĻŧāĻž āĻšāϝāĻŧāύāĻŋ 0.99

Clinical interpretation: āϰāĻ•ā§āϤāϚāĻžāĻĒ āĻ“ āĻ…āĻ•ā§āϏāĻŋāĻœā§‡āύ āĻ¸ā§āϝāĻžāϚ⧁āϰ⧇āĻļāύ āϤāĻžā§ŽāĻ•ā§āώāĻŖāĻŋāĻ•āĻ­āĻžāĻŦ⧇ āφāĻļāĻ™ā§āĻ•āĻžāϜāύāĻ• āύāϝāĻŧāĨ¤ Pulse 96 bpm āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ• āϏ⧀āĻŽāĻžāϰ āϊāĻ°ā§āĻ§ā§āĻŦāĻĻāĻŋāϕ⧇, āĻ•āĻŋāĻ¨ā§āϤ⧁ āĻļ⧁āϧ⧁ āĻāχ āĻŽāĻžāύ āĻĻāĻŋāϝāĻŧ⧇ Tachycardia āύāĻŋāĻ°ā§āĻŖāϝāĻŧ āĻ•āϰāĻž āϝāĻžāϝāĻŧ āύāĻžāĨ¤ āĻŦāϝāĻŧāϏ, āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻž, āĻŦā§āϝāĻĨāĻž āĻāĻŦāĻ‚ āĻ“āώ⧁āϧ⧇āϰ āĻĒāĻžāĻ°ā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋāϝāĻŧāĻž āĻŦāĻŋāĻŦ⧇āϚāύāĻž āĻ•āϰāĻž āĻĻāϰāĻ•āĻžāϰāĨ¤

Confidence: 0.95


2. Chief Complaints (C/C) — āϰ⧋āĻ—ā§€āϰ āĻĒā§āϰāϧāĻžāύ āĻ…āĻ­āĻŋāϝ⧋āĻ—

āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇āϰ āĻŦāĻžāĻŽ āĻĒāĻžāĻļ⧇ C/C āĻšāĻŋāϏ⧇āĻŦ⧇ āĻĒāĻžāρāϚāϟāĻŋ āĻ…āĻ­āĻŋāϝ⧋āĻ— āϞ⧇āĻ–āĻž āφāϛ⧇āĨ¤

No. Doctor’s Written C/C āĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨ Clinical Significance
1 Nocturia āϰāĻžāϤ⧇ āϘ⧁āĻŽ āĻĨ⧇āϕ⧇ āωāϠ⧇ āĻĒā§āϰāĻ¸ā§āϰāĻžāĻŦ āĻ•āϰāϤ⧇ āĻšāϝāĻŧ OAB, UTI, nocturnal polyuria, diabetes āĻŦāĻž āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ•āĻžāϰāϪ⧇ āĻšāϤ⧇ āĻĒāĻžāϰ⧇
2 LBP Low Back Pain — āϕ⧋āĻŽāϰ⧇āϰ āύāĻŋāĻšā§‡āϰ āĻ…āĻ‚āĻļ⧇ āĻŦā§āϝāĻĨāĻž Musculoskeletal, degenerative āĻŦāĻž neurological āĻ•āĻžāϰāĻŖ
3 Pain — Both Shoulders āωāĻ­āϝāĻŧ āĻ•āĻžāρāϧ⧇ āĻŦā§āϝāĻĨāĻž OA, inflammatory arthritis, PMR āĻ…āĻĨāĻŦāĻž rotator cuff disease
4 Insomnia āĻ…āύāĻŋāĻĻā§āϰāĻž āĻŦā§āϝāĻĨāĻž, Nocturia āĻ…āĻĨāĻŦāĻž āĻ…āĻ¨ā§āϝ āϏāĻŽāĻ¸ā§āϝāĻžāϰ āĻ•āĻžāϰāϪ⧇ āϘ⧁āĻŽā§‡āϰ āĻŦā§āϝāĻžāϘāĻžāϤ
5 Common Cold āϏāĻžāϧāĻžāϰāĻŖ āϏāĻ°ā§āĻĻāĻŋ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ Viral Upper Respiratory Tract Infection

Confidence: 0.99 — Prescription transcription.

Clinical significance

Nocturia: āĻāϟāĻŋ āĻāĻ•āϟāĻŋ āωāĻĒāϏāĻ°ā§āĻ—, āϰ⧋āϗ⧇āϰ āύāĻžāĻŽ āύāϝāĻŧāĨ¤ āϰāĻžāϤ⧇ āĻ•āϤāĻŦāĻžāϰ āĻĒā§āϰāĻ¸ā§āϰāĻžāĻŦ āĻšāϝāĻŧ, āĻĒā§āϰāϤāĻŋāĻŦāĻžāϰ āĻ•āϤāϟāĻž āĻĒā§āϰāĻ¸ā§āϰāĻžāĻŦ āĻšāϝāĻŧ āĻāĻŦāĻ‚ āĻĒā§āϰāĻ¸ā§āϰāĻžāĻŦ⧇āϰ āĻŦ⧇āĻ— āύāĻŋāϝāĻŧāĻ¨ā§āĻ¤ā§āϰāĻŖ āĻ•āϰāĻž āϝāĻžāϝāĻŧ āĻ•āĻŋ āύāĻžâ€”āĻāϏāĻŦ āϤāĻĨā§āϝ āĻ›āĻžāĻĄāĻŧāĻž Overactive Bladder āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻž āϝāĻžāϝāĻŧ āύāĻžāĨ¤

Bilateral shoulder pain: āĻāχ āĻŦāϝāĻŧāϏ⧇ Osteoarthritis, Rotator Cuff Disease, Rheumatoid Arthritis āĻāĻŦāĻ‚ Polymyalgia Rheumatica āĻŦāĻŋāĻŦ⧇āϚāύāĻž āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤ āĻļ⧁āϧ⧁ āĻĻ⧁āχ āĻ•āĻžāρāϧ⧇ āĻŦā§āϝāĻĨāĻž āĻĨāĻžāĻ•āϞ⧇āχ Rheumatoid Arthritis āĻšāϝāĻŧ āύāĻžāĨ¤

Insomnia: Nocturia āĻāĻŦāĻ‚ āĻĻā§€āĻ°ā§āϘāĻ¸ā§āĻĨāĻžāϝāĻŧā§€ āĻŦā§āϝāĻĨāĻž āϘ⧁āĻŽā§‡āϰ āĻŦā§āϝāĻžāϘāĻžāϤ āϘāϟāĻžāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤ āϤāĻŦ⧇ āĻ…āύāĻŋāĻĻā§āϰāĻžāϰ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻ•āĻžāϰāĻŖ āĻāχ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āĻĒā§āϰāϤāĻŋāĻˇā§āĻ āĻŋāϤ āĻšāϝāĻŧāύāĻŋāĨ¤

Confidence: 0.91 — General clinical interpretation; patient-specific etiology remains unconfirmed.


3. Clinical History Review — O/H, D/H, M/H, O/S/E

āĻāĻ–āĻžāύ⧇ Not documented āĻāĻŦāĻ‚ Negative history āĻāĻ• āĻŦāĻŋāώāϝāĻŧ āύāϝāĻŧāĨ¤ āϕ⧋āύ⧋ āχāϤāĻŋāĻšāĻžāϏ āϞ⧇āĻ–āĻž āύāĻž āĻĨāĻžāĻ•āϞ⧇ āϏ⧇āϟāĻŋāϕ⧇ āϰ⧋āĻ—ā§€āϰ āχāϤāĻŋāĻšāĻžāϏ āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ• āĻŦāϞ⧇ āϧāϰāĻž āϝāĻžāĻŦ⧇ āύāĻžāĨ¤

History/Examination Doctor’s Documentation Assessment
O/H — Obstetric History Not documented āϏāĻ¨ā§āϤāĻžāύāϧāĻžāϰāĻŖ āĻ“ āĻĒā§āϰāϏāĻŦ⧇āϰ āχāϤāĻŋāĻšāĻžāϏ āĻ…āϜāĻžāύāĻž
D/H — Drug History Not documented separately āĻĒā§‚āĻ°ā§āĻŦ āĻĨ⧇āϕ⧇ āϕ⧀ āĻ“āώ⧁āϧ āϖ⧇āϤ⧇āύ, āϜāĻžāύāĻž āύ⧇āχ
M/H — Medical History Not documented DM, HTN, CKD, RA, CAD-āĻāϰ āχāϤāĻŋāĻšāĻžāϏ āĻ…āϜāĻžāύāĻž
O/S/E — Systemic Examination Not documented āĻĒā§‚āĻ°ā§āĻŖ Systemic Examination āύ⧇āχ
O/G/E — General Examination BP, Pulse, SpO₂ documented āϏ⧀āĻŽāĻŋāϤ Vital Signs āĻĒāĻžāĻ“āϝāĻŧāĻž āϗ⧇āϛ⧇
Surgical History Not documented āĻ…āĻĒāĻžāϰ⧇āĻļāύ⧇āϰ āχāϤāĻŋāĻšāĻžāϏ āĻ…āϜāĻžāύāĻž
Family History Not documented āĻĒāĻžāϰāĻŋāĻŦāĻžāϰāĻŋāĻ• āϰ⧋āϗ⧇āϰ āχāϤāĻŋāĻšāĻžāϏ āĻ…āϜāĻžāύāĻž
Allergy History Not documented āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϰ āϤāĻĨā§āϝ āύ⧇āχ
Menopausal History Not documented Menopause-āϏāĻ‚āĻ•ā§āϰāĻžāĻ¨ā§āϤ āχāϤāĻŋāĻšāĻžāϏ āύ⧇āχ
Smoking/Alcohol History Not documented āϕ⧋āύ⧋ āϤāĻĨā§āϝ āύ⧇āχ

Confidence: 0.99 — Documentation assessment.

History that must be obtained

āĻĒā§āϰāĻĨāĻŽāϤ, Nocturia āĻ•āϤāĻĻāĻŋāύ āϧāϰ⧇ āĻšāĻšā§āϛ⧇, āϰāĻžāϤ⧇ āĻ•āϤāĻŦāĻžāϰ āĻĒā§āϰāĻ¸ā§āϰāĻžāĻŦ āĻšāϝāĻŧ, āĻœā§āĻŦāĻžāϞāĻžāĻĒā§‹āĻĄāĻŧāĻž, Urgency, Urinary Incontinence āĻŦāĻž āĻĒā§āϰāĻ¸ā§āϰāĻžāĻŦ āφāϟāϕ⧇ āϝāĻžāĻ“āϝāĻŧāĻžāϰ āϏāĻŽāĻ¸ā§āϝāĻž āφāϛ⧇ āĻ•āĻŋ āύāĻž āϜāĻžāύāϤ⧇ āĻšāĻŦ⧇āĨ¤

āĻĻā§āĻŦāĻŋāϤ⧀āϝāĻŧāϤ, āĻ•āĻžāρāϧ⧇āϰ āĻŦā§āϝāĻĨāĻžāϰ āϏāĻ™ā§āϗ⧇ āϏāĻ•āĻžāϞ⧇ āϜāϝāĻŧ⧇āĻ¨ā§āϟ āĻļāĻ•ā§āϤ āĻšāϝāĻŧ⧇ āĻĨāĻžāĻ•āĻž, āĻĢā§‹āϞāĻž, āĻšāĻžāϤ⧇āϰ āϛ⧋āϟ āϜāϝāĻŧ⧇āĻ¨ā§āĻŸā§‡ āĻŦā§āϝāĻĨāĻž āĻ…āĻĨāĻŦāĻž āφāϗ⧇ Rheumatoid Arthritis-āĻāϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āχāϤāĻŋāĻšāĻžāϏ āφāϛ⧇ āĻ•āĻŋ āύāĻž āϜāĻžāύāϤ⧇ āĻšāĻŦ⧇āĨ¤

āϤ⧃āϤ⧀āϝāĻŧāϤ, āĻĒā§‚āĻ°ā§āĻŦ⧇āϰ DMARD āĻŦā§āϝāĻŦāĻšāĻžāϰ, Methotrexate treatment history, Kidney Disease, Tuberculosis, Hepatitis B/C, Cardiovascular Disease āĻāĻŦāĻ‚ āĻŦāĻ°ā§āϤāĻŽāĻžāύ āĻ“āώ⧁āϧ⧇āϰ āϤāĻžāϞāĻŋāĻ•āĻž āϜāĻžāύāϤ⧇ āĻšāĻŦ⧇āĨ¤

Confidence: 0.96 — Recommended clinical history.


4. O/E — On Examination

āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āϤāĻŋāύāϟāĻŋ āĻĒāĻ°ā§āϝāĻŦ⧇āĻ•ā§āώāĻŖ āϞ⧇āĻ–āĻž āĻšāϝāĻŧ⧇āϛ⧇āĨ¤

4.1 Blood Pressure: 110/70 mmHg

Interpretation: āĻĒā§āϰāĻĻāĻ¤ā§āϤ āϰāĻ•ā§āϤāϚāĻžāĻĒ āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ• āϏ⧀āĻŽāĻžāϰ āĻŽāĻ§ā§āϝ⧇āĨ¤ āϤāĻŦ⧇ āĻŦāϝāĻŧāĻ¸ā§āĻ• āϰ⧋āĻ—ā§€āϰ Orthostatic Hypotension āφāϛ⧇ āĻ•āĻŋ āύāĻž āϝāĻžāϚāĻžāχ āĻ•āϰāĻž āωāĻĒāĻ•āĻžāϰ⧀, āĻŦāĻŋāĻļ⧇āώāϤ āĻŽāĻžāĻĨāĻž āĻ˜ā§‹āϰāĻž āĻŦāĻž āĻĒāĻĄāĻŧ⧇ āϝāĻžāĻ“āϝāĻŧāĻžāϰ āχāϤāĻŋāĻšāĻžāϏ āĻĨāĻžāĻ•āϞ⧇āĨ¤

Confidence: 0.96

4.2 Pulse: 96 bpm

Interpretation: āĻāϟāĻŋ āĻĒā§āϰāĻžāĻĒā§āϤāĻŦāϝāĻŧāĻ¸ā§āĻ•āĻĻ⧇āϰ āĻĒā§āϰāϚāϞāĻŋāϤ resting pulse range-āĻāϰ āĻŽāĻ§ā§āϝ⧇ āϰāϝāĻŧ⧇āϛ⧇, āϝāĻĻāĻŋāĻ“ āωāĻšā§āϚ āϏ⧀āĻŽāĻžāϰ āĻ•āĻžāĻ›āĻžāĻ•āĻžāĻ›āĻŋāĨ¤ āĻŦā§āϝāĻĨāĻž, āωāĻĻā§āĻŦ⧇āĻ—, āĻœā§āĻŦāϰ āĻŦāĻž āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ•āĻžāϰāϪ⧇ Pulse āĻŦ⧇āĻĄāĻŧ⧇ āϝ⧇āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Confidence: 0.97

4.3 SpO₂: 99%

Interpretation: āĻĒā§āϰāĻĻāĻ¤ā§āϤ āĻ…āĻ•ā§āϏāĻŋāĻœā§‡āύ āĻ¸ā§āϝāĻžāϚ⧁āϰ⧇āĻļāύ āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ•āĨ¤ āϤāĻŦ⧇ āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ• SpO₂ āĻĻā§āĻŦāĻžāϰāĻž āĻļā§āĻŦāĻžāϏāϤāĻ¨ā§āĻ¤ā§āϰ⧇āϰ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āϏāĻŽā§āĻĒā§‚āĻ°ā§āĻŖāĻ­āĻžāĻŦ⧇ āĻŦāĻžāĻĻ āĻĻ⧇āĻ“āϝāĻŧāĻž āϝāĻžāϝāĻŧ āύāĻžāĨ¤

Confidence: 0.98

Missing examinations

Abdominal Examination, Costovertebral Angle Tenderness, Joint Examination, Neurological Examination, Temperature, Respiratory Examination āĻāĻŦāĻ‚ Post-Void Residual Assessment āύāĻĨāĻŋāϭ⧁āĻ•ā§āϤ āύ⧇āχāĨ¤

Confidence: 0.99


5. Doctor-Advised Investigations — āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āϤāĻžāϞāĻŋāĻ•āĻž āĻ“ āĻŦā§āϝāĻžāĻ–ā§āϝāĻž

āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇āϰ AD āĻ…āĻ‚āĻļ⧇ āĻĒāĻžāρāϚāϟāĻŋ āĻĒāϰ⧀āĻ•ā§āώāĻž āϰāϝāĻŧ⧇āϛ⧇āĨ¤

āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ: āĻāĻ–āĻžāύ⧇ āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āύāĻŋāĻ°ā§āĻĻ⧇āĻļ āφāϛ⧇, āĻ•āĻŋāĻ¨ā§āϤ⧁ āϕ⧋āύ⧋ āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āĻĢāϞāĻžāĻĢāϞ āĻŦāĻž āϰāĻŋāĻĒā§‹āĻ°ā§āϟ āϏāĻ‚āϝ⧁āĻ•ā§āϤ āύ⧇āχāĨ¤

No. Investigation āĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨ Why Important
1 S. Creatinine āϰāĻ•ā§āϤ⧇ āĻ•ā§āϰāĻŋāϝāĻŧ⧇āϟāĻŋāύāĻŋāύ āĻ•āĻŋāĻĄāύāĻŋāϰ āĻ•āĻžāĻ°ā§āϝāĻ•āĻžāϰāĻŋāϤāĻž āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ
2 RA Factor āϰāĻŋāωāĻŽāĻžāϟāϝāĻŧ⧇āĻĄ āĻĢā§āϝāĻžāĻ•ā§āϟāϰ āĻĒā§āϰāĻĻāĻžāĻšāϜāύāĻŋāϤ āĻŦāĻžāϤāϰ⧋āϗ⧇āϰ āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ⧇ āϏāĻšāĻžāϝāĻŧāĻ•
3 Urine R/M/E āĻĒā§āϰāĻ¸ā§āϰāĻžāĻŦ⧇āϰ āϰ⧁āϟāĻŋāύ āĻ“ āĻŽāĻžāχāĻ•ā§āϰ⧋āĻ¸ā§āϕ⧋āĻĒāĻŋāĻ• āĻĒāϰ⧀āĻ•ā§āώāĻž Pyuria, Hematuria āĻ“ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ…āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ•āϤāĻž
4 RBS Random Blood Sugar āϰāĻ•ā§āϤ⧇ āĻ—ā§āϞ⧁āϕ⧋āĻœā§‡āϰ āĻŽāĻžāĻ¤ā§āϰāĻž
5 USG of L/A āϤāϞāĻĒ⧇āĻŸā§‡āϰ āφāĻ˛ā§āĻŸā§āϰāĻžāϏāύ⧋āĻ—ā§āϰāĻžāĻĢāĻŋ āĻŽā§‚āĻ¤ā§āϰāĻĨāϞāĻŋ āĻ“ āĻĒ⧇āϞāĻ­āĻŋāĻ• āĻ…āĻ™ā§āĻ—āϏāĻŽā§‚āĻšā§‡āϰ āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ

Confidence: 0.99 — Prescription transcription.

Investigation-wise clinical interpretation

1. Serum Creatinine: āϰ⧋āĻ—ā§€āϰ āĻŦāϝāĻŧāϏ ā§Žā§Ģ āĻŦāĻ›āϰāĨ¤ Nitrofurantoin, Mirogabalin āĻāĻŦāĻ‚ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ“āώ⧁āϧ⧇āϰ āύāĻŋāϰāĻžāĻĒāĻĻ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ⧇āϰ āϜāĻ¨ā§āϝ Creatinine-āĻāϰ āĻĒāĻžāĻļāĻžāĻĒāĻžāĻļāĻŋ eGFR āĻĻāϰāĻ•āĻžāϰāĨ¤ Creatinine āĻāĻ•āĻž āϝāĻĨ⧇āĻˇā§āϟ āύāϝāĻŧāĨ¤

Confidence: 0.99

2. Rheumatoid Factor: RA Factor positive āĻšāϞ⧇ Rheumatoid Arthritis-āĻāϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻž āĻŦāĻžāĻĄāĻŧāϤ⧇ āĻĒāĻžāϰ⧇, āĻ•āĻŋāĻ¨ā§āϤ⧁ āĻāϟāĻŋ āĻāĻ•āĻž āϰ⧋āĻ— āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰ⧇ āύāĻžāĨ¤ Negative āĻšāϞ⧇āĻ“ RA āϏāĻŽā§āĻĒā§‚āĻ°ā§āĻŖ āĻŦāĻžāĻĻ āϝāĻžāϝāĻŧ āύāĻžāĨ¤ Clinical Synovitis, Anti-CCP āĻāĻŦāĻ‚ Inflammatory Markers āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖāĨ¤

Confidence: 0.99

3. Urine R/M/E: āĻĒā§āϰāĻ¸ā§āϰāĻžāĻŦ⧇ WBC, RBC, Bacteria, Protein, Glucose āχāĻ¤ā§āϝāĻžāĻĻāĻŋ āĻĻ⧇āĻ–āĻž āϝāĻžāϝāĻŧāĨ¤ āϤāĻŦ⧇ āĻŦāϝāĻŧāĻ¸ā§āĻ• āϰ⧋āĻ—ā§€āϰ āĻĒā§āϰāĻ¸ā§āϰāĻžāĻŦ⧇ āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋāϝāĻŧāĻž āĻĒāĻžāĻ“āϝāĻŧāĻž āϗ⧇āϞ⧇āχ Symptomatic UTI āĻŦāϞāĻž āϝāĻžāϝāĻŧ āύāĻžāĨ¤

Confidence: 0.99

4. RBS: Diabetes āĻŦāĻž Hyperglycemia āĻĨāĻžāĻ•āϞ⧇ Polyuria āĻ“ Nocturia āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Confidence: 0.98

5. USG of Lower Abdomen: Bladder abnormality, bladder stone āĻāĻŦāĻ‚ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ pelvic pathology āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ⧇ āϏāĻšāĻžāϝāĻŧāĻ•āĨ¤ āϤāĻŦ⧇ Post-Void Residual (PVR) āĻĒāϰāĻŋāĻŽāĻžāĻĒ āφāϞāĻžāĻĻāĻžāĻ­āĻžāĻŦ⧇ āωāĻ˛ā§āϞ⧇āĻ– āĻŦāĻž āϏāĻŽā§āĻĒāĻ¨ā§āύ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Confidence: 0.96

Additional investigations I would consider

āϰ⧋āĻ—ā§€āϰ āχāϤāĻŋāĻšāĻžāϏ āĻ“ āĻļāĻžāϰ⧀āϰāĻŋāĻ• āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āĻ­āĻŋāĻ¤ā§āϤāĻŋāϤ⧇:

  • Urine Culture and Sensitivity — Symptomatic UTI āϏāĻ¨ā§āĻĻ⧇āĻš āĻšāϞ⧇āĨ¤
  • CBC with Differential Count — āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āĻ“ āϰāĻ•ā§āϤāĻ¸ā§āĻŦāĻ˛ā§āĻĒāϤāĻž āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ⧇āĨ¤
  • ESR, CRP — Inflammatory arthritis āĻŦāĻž PMR āϏāĻ¨ā§āĻĻ⧇āĻš āĻšāϞ⧇āĨ¤
  • Anti-CCP Antibody — RA evaluation-āĻāĨ¤
  • HbA1c — Diabetes-āĻāϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻž āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ⧇āĨ¤
  • Serum Electrolytes — āĻĒā§āϰāϝāĻŧā§‹āϜāύ āĻ…āύ⧁āϏāĻžāϰ⧇āĨ¤
  • eGFR and calculated Creatinine Clearance — Renal drug dosing-āĻāϰ āϜāĻ¨ā§āϝāĨ¤
  • Post-Void Residual and Bladder Diary — Nocturia/OAB āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ⧇āĨ¤
  • LFT, TB screening, Hepatitis B/C screening āĻ“ Lipid Profile — Tofacitinib treatment-āĻāϰ āϝāĻĨāĻžāĻ°ā§āĻĨāϤāĻž āϝāĻžāϚāĻžāχ āĻāĻŦāĻ‚ āĻĒāĻ°ā§āϝāĻŦ⧇āĻ•ā§āώāϪ⧇āϰ āϜāĻ¨ā§āϝāĨ¤

Confidence: 0.94

AUA/SUFU 2024 OAB guideline āĻ…āύ⧁āϝāĻžāϝāĻŧā§€ History, Physical Examination āĻāĻŦāĻ‚ Urinalysis āĻĒā§āϰāĻžāĻĨāĻŽāĻŋāĻ• āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ⧇āϰ āĻ…āĻ‚āĻļāĨ¤ āĻĒā§āϰāϝāĻŧā§‹āϜāύ āĻ…āύ⧁āϝāĻžāϝāĻŧā§€ PVR āĻ“ Bladder Diary āĻ•āϰāĻž āĻšāϝāĻŧāĨ¤


6. Disease Definition, Etiology & Pathophysiology

6.1 Nocturia — āϰāĻžāϤ⧇ āĻĒā§āϰāĻ¸ā§āϰāĻžāĻŦ⧇āϰ āϜāĻ¨ā§āϝ āϘ⧁āĻŽ āĻ­āĻžāĻ™āĻž

Definition: āϘ⧁āĻŽā§‡āϰ āĻĒā§āϰāϧāĻžāύ āϏāĻŽāϝāĻŧ⧇ āĻĒā§āϰāĻ¸ā§āϰāĻžāĻŦ āĻ•āϰāĻžāϰ āϜāĻ¨ā§āϝ āĻāĻ• āĻŦāĻž āĻāĻ•āĻžāϧāĻŋāĻ•āĻŦāĻžāϰ āϘ⧁āĻŽ āĻĨ⧇āϕ⧇ āĻ“āĻ āĻžāϕ⧇ Nocturia āĻŦāϞāĻž āĻšāϝāĻŧāĨ¤

āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻ•āĻžāϰāĻŖāϗ⧁āϞ⧋āϰ āĻŽāĻ§ā§āϝ⧇ āϰāϝāĻŧ⧇āϛ⧇:

  • Nocturnal Polyuria
  • Overactive Bladder
  • Urinary Tract Infection
  • Diabetes Mellitus
  • Reduced Functional Bladder Capacity
  • Incomplete Bladder Emptying
  • Sleep Disorders
  • Heart Failure-associated nocturnal diuresis

Patient-specific confidence in the underlying cause: 0.50

6.2 Overactive Bladder (OAB) — āĻ…āϤāĻŋāϏāĻ•ā§āϰāĻŋāϝāĻŧ āĻŽā§‚āĻ¤ā§āϰāĻĨāϞāĻŋ

Definition: Urinary Urgency āĻĒā§āϰāϧāĻžāύ āωāĻĒāϏāĻ°ā§āĻ— āĻšāĻŋāϏ⧇āĻŦ⧇ āωāĻĒāĻ¸ā§āĻĨāĻŋāϤ āĻĨāĻžāϕ⧇, āϏāĻžāϧāĻžāϰāĻŖāϤ Frequency āĻ“ Nocturia-āϏāĻš; Urgency Incontinence āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇ āĻ…āĻĨāĻŦāĻž āύāĻžāĻ“ āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤ UTI āĻŦāĻž āĻ…āĻ¨ā§āϝ āϏ⧁āĻ¸ā§āĻĒāĻˇā§āϟ pathology āĻĻā§āĻŦāĻžāϰāĻž āωāĻĒāϏāĻ°ā§āĻ— āĻŦā§āϝāĻžāĻ–ā§āϝāĻž āĻ•āϰāĻž āϗ⧇āϞ⧇ idiopathic OAB āύāĻŋāĻ°ā§āĻŖāϝāĻŧ āĻ•āϰāĻž āωāϚāĻŋāϤ āύāϝāĻŧāĨ¤

Pathophysiology: Detrusor muscle āĻ“ bladder sensory signaling-āĻāϰ āĻ…āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ•āϤāĻž āĻĒā§āϰāĻ¸ā§āϰāĻžāĻŦ⧇āϰ āϤ⧀āĻŦā§āϰ āĻŦ⧇āϗ⧇āϰ āϏāĻ™ā§āϗ⧇ āϏāĻŽā§āĻĒāĻ°ā§āĻ•āĻŋāϤ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

āĻāχ āϰ⧋āĻ—ā§€āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇: Mirabegron āĻ“ Flavoxate āĻŦā§āϝāĻŦāĻšāĻžāϰ OAB-āϜāĻžāϤ⧀āϝāĻŧ āωāĻĒāϏāĻ°ā§āϗ⧇āϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āχāĻ™ā§āĻ—āĻŋāϤ āĻĻ⧇āϝāĻŧ, āĻ•āĻŋāĻ¨ā§āϤ⧁ Urgency āϞ⧇āĻ–āĻž āύ⧇āχāĨ¤

Confidence in suspected OAB: 0.56

6.3 Urinary Tract Infection (UTI) — āĻŽā§‚āĻ¤ā§āϰāύāĻžāϞ⧀āϰ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ

Definition: āĻŽā§‚āĻ¤ā§āϰāϤāĻ¨ā§āĻ¤ā§āϰ⧇ āĻœā§€āĻŦāĻžāϪ⧁āϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āϏāĻ™ā§āϗ⧇ āϏāĻžāĻŽāĻžā§āϜāĻ¸ā§āϝāĻĒā§‚āĻ°ā§āĻŖ Clinical Symptoms āĻāĻŦāĻ‚ āĻĒā§āϰāĻžāϏāĻ™ā§āĻ—āĻŋāĻ• āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āĻĢāϞāĻžāĻĢāϞ āĻĨāĻžāĻ•āϞ⧇ Symptomatic UTI āύāĻŋāĻ°ā§āĻŖāϝāĻŧ āĻ•āϰāĻž āĻšāϝāĻŧāĨ¤

Pathophysiology: āϏāĻžāϧāĻžāϰāĻŖāϤ Enteric Bacteria, āĻŦāĻŋāĻļ⧇āώāϤ Escherichia coli, āĻŽā§‚āĻ¤ā§āϰāύāĻžāϞ⧀ āĻĻāĻŋāϝāĻŧ⧇ āĻĒā§āϰāĻŦ⧇āĻļ āĻ•āϰ⧇ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āϘāϟāĻžāϝāĻŧāĨ¤

āĻāχ āϰ⧋āĻ—ā§€āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇: Nitrofurantoin āĻĻ⧇āĻ“āϝāĻŧāĻž āĻšāϝāĻŧ⧇āϛ⧇, āϝāĻž UTI āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āĻ“āώ⧁āϧāĨ¤ āĻ•āĻŋāĻ¨ā§āϤ⧁ Nocturia āĻ›āĻžāĻĄāĻŧāĻž Dysuria, Suprapubic Pain, Fever āĻ…āĻĨāĻŦāĻž Urine Culture result āύ⧇āχāĨ¤

āϏ⧁āϤāϰāĻžāĻ‚ Confirmed UTI āϞ⧇āĻ–āĻž āϝāĻžāĻŦ⧇ āύāĻžāĨ¤

Confidence in possible UTI: 0.43

IDSA 2019 guideline āĻ…āύ⧁āϝāĻžāϝāĻŧā§€ āĻŦāϝāĻŧāĻ¸ā§āĻ• āϰ⧋āĻ—ā§€āϰ Asymptomatic Bacteriuria āϏāĻžāϧāĻžāϰāĻŖāϤ antibiotic āĻĻāĻŋāϝāĻŧ⧇ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āĻ•āϰāĻž āωāϚāĻŋāϤ āύāϝāĻŧ, āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻŦā§āϝāϤāĻŋāĻ•ā§āϰāĻŽ āĻ›āĻžāĻĄāĻŧāĻžāĨ¤

6.4 Rheumatoid Arthritis (RA) — āϰāĻŋāωāĻŽāĻžāϟāϝāĻŧ⧇āĻĄ āφāĻ°ā§āĻĨā§āϰāĻžāχāϟāĻŋāϏ

Definition: āĻĻā§€āĻ°ā§āϘāĻ¸ā§āĻĨāĻžāϝāĻŧā§€ Systemic Autoimmune Inflammatory Disease, āϝāĻž āĻĒā§āϰāϧāĻžāύāϤ Synovial Joints-āĻ āĻĒā§āϰāĻĻāĻžāĻš āϏ⧃āĻˇā§āϟāĻŋ āĻ•āϰ⧇āĨ¤

Pathophysiology: Autoimmune Synovitis, Cytokine activation āĻāĻŦāĻ‚ progressive joint damage āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

āĻāχ āϰ⧋āĻ—ā§€āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇: Tofacitinib āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ“ RA Factor test-āĻāϰ āύāĻŋāĻ°ā§āĻĻ⧇āĻļ RA-āϏāĻ‚āĻ•ā§āϰāĻžāĻ¨ā§āϤ āϏāĻ¨ā§āĻĻ⧇āĻš āĻŦāĻž āĻĒā§‚āĻ°ā§āĻŦ⧇āϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻž āϤ⧈āϰāĻŋ āĻ•āϰ⧇āĨ¤ āĻ•āĻŋāĻ¨ā§āϤ⧁ Clinical Synovitis, Small-Joint Involvement, Morning Stiffness, RF result, Anti-CCP āĻāĻŦāĻ‚ āĻĒā§‚āĻ°ā§āĻŦ⧇āϰ RA diagnosis āύ⧇āχāĨ¤

Conclusion: RA āĻāĻ•āϟāĻŋ differential diagnosis; āύāĻŋāĻļā§āϚāĻŋāϤ āϰ⧋āĻ— āύāϝāĻŧāĨ¤

Confidence in confirmed RA: 0.25 — Insufficient evidence.


7. 🟩 Prescribed Drug Analysis — MedEx āĻ…āύ⧁āϝāĻžāϝāĻŧā§€

āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āĻŽā§‹āϟ ā§§ā§ĻāϟāĻŋ āĻ“āώ⧁āϧ/āĻĒā§āϰāĻ¸ā§āϤ⧁āϤāĻŋ āϰāϝāĻŧ⧇āϛ⧇āĨ¤ āĻĒā§āϰāϤāĻŋāϟāĻŋ āĻĒ⧃āĻĨāĻ•āĻ­āĻžāĻŦ⧇ MedEx Bangladesh-āĻāϰ āϤāĻĨā§āϝ⧇āϰ āϏāĻ™ā§āϗ⧇ āĻŽāĻŋāϞāĻŋāϝāĻŧ⧇ āĻŦāĻŋāĻļā§āϞ⧇āώāĻŖ āĻ•āϰāĻž āĻšāϞ⧋āĨ¤

Table 1: Original Prescription — Exact Drug Review

No. Prescribed Medicine Generic Written Dose Written Duration
1 Nintoin SR 100 mg Nitrofurantoin 1+0+1 7 days
2 Uroza 200 mg Flavoxate 1+0+1 1 month
3 M-Beg 25 mg Mirabegron 1+0+0 1 month
4 Sudac 200 mg Sulindac 1+0+1 10 days
5 Tofatin XR 11 mg Tofacitinib 0+0+1 20 days
6 Merolin 5 mg* Mirogabalin 1+0+1 15 days
7 Zo-MUPS 40 mg Esomeprazole 1+0+1 15 days
8 Gavirad Suspension* Alginate combination 2 teaspoons × 3 15 days
9 Brofex TS Dextromethorphan Polistirex 2 teaspoons × 3 15 days
10 Voligel Max 2% Diclofenac Sodium Apply twice daily Duration not specified

*Merolin āĻ“ Gavirad: āĻšāĻžāϤ⧇āϰ āϞ⧇āĻ–āĻž āĻ“ MedEx-āĻāϰ brand name āĻŽāĻŋāϞāĻŋāϝāĻŧ⧇ āĻĒāĻĄāĻŧāĻž āĻšāϝāĻŧ⧇āϛ⧇āĨ¤ āĻ“āώ⧁āϧ⧇āϰ āĻĒā§āϝāĻžāϕ⧇āϟ āĻĻāĻŋāϝāĻŧ⧇ āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻž āωāϚāĻŋāϤāĨ¤

Transcription confidence: 0.94; Merolin/Gavirad identification confidence: 0.83.


7.1 Medicine No. 1 — Nintoin SR 100 mg

1. Generic Name: Nitrofurantoin — āύāĻžāχāĻŸā§āϰ⧋āĻĢāĻŋāωāϰāĻžāύāĻŸā§‹āχāύāĨ¤

2. Brand Name: Nintoin SR 100 mg.

3. MedEx Alternate Brands: Nitrobac SR 100 mg, Nitrofur SR 100 mg.

4. MedEx Therapeutic Class: Systemic Urinary Anti-infective.

5. Pharmacological Class: Nitrofuran antibacterial antibiotic.

6. Purpose: āĻŽā§‚āĻ¤ā§āϰāύāĻžāϞ⧀āϰ āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋāϝāĻŧāĻžāϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĨ¤

7. Why prescribed in this patient: Nocturia-āϰ āϏāĻ™ā§āϗ⧇ UTI āϏāĻ¨ā§āĻĻ⧇āĻš āĻ•āϰ⧇ āĻĄāĻžāĻ•ā§āϤāĻžāϰ āĻ“āώ⧁āϧāϟāĻŋ āĻĻāĻŋāϝāĻŧ⧇ āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇āύāĨ¤ āϤāĻŦ⧇ UTI āύāĻŋāĻļā§āϚāĻŋāϤ āĻšāĻ“āϝāĻŧāĻžāϰ āϤāĻĨā§āϝ āύ⧇āχāĨ¤

8. Side Effects: Nausea, vomiting, headache, gastrointestinal upset; āĻŦāĻŋāϰāϞ āĻ•āĻŋāĻ¨ā§āϤ⧁ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ Pulmonary Toxicity, Hepatotoxicity āĻ“ Peripheral NeuropathyāĨ¤

9. MedEx Link: Nintoin SR — MedEx

10. Price & Other Composition: Unit ā§ŗ23; Strip ā§ŗ230āĨ¤ āĻāĻ•āχ brand-āĻāϰ 100 mg conventional tablet, 50 mg capsule āĻāĻŦāĻ‚ suspension āϰāϝāĻŧ⧇āϛ⧇āĨ¤

11. Mechanism: Bacterial proteins āĻ“ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ macromolecules-āĻāϰ āĻ•āĻžāĻ°ā§āϝāĻ•āĻžāϰāĻŋāϤāĻž āĻŦā§āϝāĻžāĻšāϤ āĻ•āϰ⧇āĨ¤

12. Indications: Susceptible organisms āĻĻā§āĻŦāĻžāϰāĻž āϏ⧃āĻˇā§āϟ Lower UTIāĨ¤

13. Interactions & Contraindications: Magnesium Trisilicate antacid āĻ“ Probenecid-āĻāϰ āϏāĻ™ā§āϗ⧇ interaction āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤ Significant renal impairment āĻāĻŦāĻ‚ Nitrofurantoin allergy āĻĨāĻžāĻ•āϞ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ…āύ⧁āĻĒāϝ⧁āĻ•ā§āϤ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

14. Precautions: Renal function āϝāĻžāϚāĻžāχ āϜāϰ⧁āϰāĻŋāĨ¤ Nitrofurantoin suspected Pyelonephritis āĻŦāĻž Urosepsis-āĻāϰ āωāĻĒāϝ⧁āĻ•ā§āϤ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āύāϝāĻŧāĨ¤

15. Dosage & Administration: Prescription: 100 mg twice daily for 7 daysāĨ¤ MedEx-āĻ SR formulation-āĻāϰ āϜāĻ¨ā§āϝ 100 mg every 12 hours āωāĻ˛ā§āϞ⧇āĻ– āφāϛ⧇āĨ¤ āĻ–āĻžāĻŦāĻžāϰ⧇āϰ āϏāĻ™ā§āϗ⧇ āĻ—ā§āϰāĻšāĻŖ āĻ•āϰāĻž āĻšāϝāĻŧāĨ¤

16. Pregnancy & Lactation: āĻ—āĻ°ā§āĻ­āĻžāĻŦāĻ¸ā§āĻĨāĻžāϰ āĻļ⧇āώ āĻĒāĻ°ā§āϝāĻžāϝāĻŧ⧇ āĻāĻŦāĻ‚ āύāĻŦāϜāĻžāϤāĻ•āϕ⧇ āĻŦ⧁āϕ⧇āϰ āĻĻ⧁āϧ āĻ–āĻžāĻ“āϝāĻŧāĻžāύ⧋āϰ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻĒāϰāĻŋāĻ¸ā§āĻĨāĻŋāϤāĻŋāϤ⧇ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ āϏāϤāĻ°ā§āĻ•āϤāĻž āϰāϝāĻŧ⧇āϛ⧇; āĻŦāĻ°ā§āϤāĻŽāĻžāύ āϰ⧋āĻ—ā§€āϰ āĻŦāϝāĻŧāϏ⧇āϰ āĻ•āĻžāϰāϪ⧇ āĻŦāĻŋāώāϝāĻŧāϟāĻŋ clinically applicable āύāϝāĻŧāĨ¤

Clinical Verdict: āĻ“āώ⧁āϧ⧇āϰ UTI-āϏāĻ‚āĻ•ā§āϰāĻžāĻ¨ā§āϤ āĻŦā§āϝāĻŦāĻšāĻžāϰ āϏāĻ āĻŋāĻ• āĻšāϞ⧇āĻ“ āϰ⧋āĻ—ā§€āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ infection confirmation āĻāĻŦāĻ‚ eGFR āϝāĻžāϚāĻžāχ āĻ…āĻĒāϰāĻŋāĻšāĻžāĻ°ā§āϝāĨ¤

Confidence: 0.98 — Drug identification; 0.44 — Patient-specific indication.


7.2 Medicine No. 2 — Uroza 200 mg

1. Generic: Flavoxate Hydrochloride.

2. Brand: Uroza 200 mg.

3. Alternate Brands: Urilax 200 mg, Flavox 200 mg.

4. MedEx Therapeutic Class: BPH/Urinary Retention/Urinary Incontinence.

5. Pharmacological Class: Urinary Antispasmodic; antimuscarinic properties āϰāϝāĻŧ⧇āϛ⧇āĨ¤

6. Purpose: Bladder spasm āĻ“ urinary urgency/frequency-āϜāĻžāϤ⧀āϝāĻŧ āωāĻĒāϏāĻ°ā§āĻ— āĻ•āĻŽāĻžāύ⧋āĨ¤

7. Why prescribed: āϰ⧋āĻ—ā§€āϰ Nocturia-āϰ āϏāĻ™ā§āϗ⧇ bladder irritation āĻŦāĻž storage symptoms āϏāĻ¨ā§āĻĻ⧇āĻš āĻ•āϰāĻž āĻšāϝāĻŧ⧇ āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

8. Side Effects: Dry mouth, constipation, dizziness, blurred vision, confusion, palpitations āĻ“ urinary retentionāĨ¤

9. MedEx Link: Uroza 200 mg — MedEx

10. Price & Composition: Unit ā§ŗ18; Strip ā§ŗ180āĨ¤ Flavoxate 100 mg āĻ…āĻ¨ā§āϝ brand-āĻ āĻĒāĻžāĻ“āϝāĻŧāĻž āϝāĻžāϝāĻŧāĨ¤

11. Mechanism: āĻŽā§‚āĻ¤ā§āϰāĻĨāϞāĻŋāϰ smooth-muscle tone āĻāĻŦāĻ‚ muscarinic signaling āĻ•āĻŽāĻŋāϝāĻŧ⧇ āωāĻĒāϏāĻ°ā§āĻ— āĻĒā§āϰāĻļāĻŽāύ⧇ āϏāĻšāĻžāϝāĻŧāϤāĻž āĻ•āϰ⧇āĨ¤

12. Indications: Dysuria, urgency, nocturia, urinary frequency āĻāĻŦāĻ‚ cystitis-āϏāĻ‚āĻ•ā§āϰāĻžāĻ¨ā§āϤ bladder discomfort-āĻāϰ symptomatic reliefāĨ¤

13. Interaction & Contraindications: Obstructive Uropathy, gastrointestinal obstruction āĻāĻŦāĻ‚ urinary retention-āϏāĻ‚āĻ•ā§āϰāĻžāĻ¨ā§āϤ āĻĒāϰāĻŋāĻ¸ā§āĻĨāĻŋāϤāĻŋāϤ⧇ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ āϏāϤāĻ°ā§āĻ•āϤāĻž/contraindication āϰāϝāĻŧ⧇āϛ⧇āĨ¤

14. Precautions: ā§Žā§Ģ āĻŦāĻ›āϰ āĻŦāϝāĻŧāϏ⧇ Anticholinergic Adverse Effects, confusion, glaucoma-related risks āĻ“ falls āĻŦāĻŋāĻŦ⧇āϚāύāĻž āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

15. Dosage: Prescription āĻ…āύ⧁āϝāĻžāϝāĻŧā§€ 200 mg twice daily for one monthāĨ¤ MedEx-āĻ āϏāĻžāϧāĻžāϰāĻŖāĻ­āĻžāĻŦ⧇ 100–200 mg āĻĻāĻŋāύ⧇ ā§Šâ€“ā§Ē āĻŦāĻžāϰ āĻŦāĻ°ā§āĻŖāĻŋāϤ āĻšāϞ⧇āĻ“ āϰ⧋āĻ—ā§€āϰ āĻŦāϝāĻŧāϏ āĻ“ tolerability āĻ…āύ⧁āϝāĻžāϝāĻŧā§€ āϏāĻŋāĻĻā§āϧāĻžāĻ¨ā§āϤ āύāĻŋāϤ⧇ āĻšāϝāĻŧāĨ¤

16. Pregnancy & Lactation: āĻĒāĻ°ā§āϝāĻžāĻĒā§āϤ āϤāĻĨā§āϝ āϏ⧀āĻŽāĻŋāϤ; āĻĒā§āϰāϝāĻŧā§‹āϜāύ āĻšāϞ⧇ āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ āĻĻāϰāĻ•āĻžāϰāĨ¤ āĻāχ āϰ⧋āĻ—ā§€āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āĻĒā§āϰāϝ⧋āĻœā§āϝ āύāϝāĻŧāĨ¤

Clinical Verdict: Nocturia-āϰ symptomatic management-āĻāϰ āϏāĻ™ā§āϗ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āϏāĻžāĻŽāĻžā§āϜāĻ¸ā§āϝāĻĒā§‚āĻ°ā§āĻŖāĨ¤ āϤāĻŦ⧇ PVR āĻ“ cognitive assessment āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖāĨ¤

Confidence: 0.98 — Pharmacology; 0.72 — Intended symptom target.


7.3 Medicine No. 3 — M-Beg 25 mg

1. Generic: Mirabegron.

2. Brand: M-Beg 25 mg XR.

3. Alternate Brands: Betmira ER 25 mg, Uroben XR 25 mg, Miragon 25 mg.

4. MedEx Therapeutic Class: BPH/Urinary Retention/Urinary Incontinence; β₃-Adrenergic Receptor Agonist.

5. Pharmacological Class: Selective Beta-3 Adrenergic Agonist.

6. Purpose: Overactive Bladder-āĻāϰ Urgency, Frequency āĻāĻŦāĻ‚ Urge Incontinence āĻ•āĻŽāĻžāύ⧋āĨ¤

7. Why prescribed: āϰ⧋āĻ—ā§€āϰ Nocturia āĻ“ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ bladder storage symptoms-āĻāϰ āϜāĻ¨ā§āϝāĨ¤

8. Side Effects: Increased blood pressure, tachycardia, headache āĻāĻŦāĻ‚ urinary retentionāĨ¤

9. MedEx Link: M-Beg 25 mg — MedEx

10. Price & Composition: Unit ā§ŗ30; Strip ā§ŗ300āĨ¤ āĻāĻ•āχ brand-āĻ 50 mg XR āϰāϝāĻŧ⧇āϛ⧇āĨ¤

11. Mechanism: Bladder detrusor muscle-āĻāϰ Beta-3 receptors stimulate āĻ•āϰ⧇ bladder storage phase-āĻ relaxation āĻŦāĻžāĻĄāĻŧāĻžāϝāĻŧāĨ¤

12. Indications: Adult Overactive Bladder Syndrome.

13. Interactions & Contraindications: CYP2D6 substrate drugs-āĻāϰ exposure āĻŦāĻžāĻĄāĻŧāĻžāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤ Severe uncontrolled hypertension-āĻ contraindicatedāĨ¤

14. Precautions: BP, pulse, urinary retention āĻāĻŦāĻ‚ renal function āĻĒāĻ°ā§āϝāĻŦ⧇āĻ•ā§āώāĻŖ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

15. Dosage: Prescription: 25 mg once daily for one monthāĨ¤ MedEx āĻ…āύ⧁āϝāĻžāϝāĻŧā§€ āĻāϟāĻŋ āĻĒā§āϰāϚāϞāĻŋāϤ starting doseāĨ¤ XR tablet āϭ⧇āϙ⧇ āĻŦāĻž āϚāĻŋāĻŦāĻŋāϝāĻŧ⧇ āĻ–āĻžāĻ“āϝāĻŧāĻž āωāϚāĻŋāϤ āύāϝāĻŧāĨ¤

16. Pregnancy & Lactation: Pregnancy āĻāĻŦāĻ‚ breastfeeding-āĻ āϏāĻžāϧāĻžāϰāĻŖāϤ recommended āύāϝāĻŧ; āĻŦāĻ°ā§āϤāĻŽāĻžāύ āϰ⧋āĻ—ā§€āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āĻĒā§āϰāϝ⧋āĻœā§āϝ āύāϝāĻŧāĨ¤

Clinical Verdict: Suspected OAB-āĻāϰ āϜāĻ¨ā§āϝ āϝ⧁āĻ•ā§āϤāĻŋāϏāĻ‚āĻ—āϤ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž, āĻ•āĻŋāĻ¨ā§āϤ⧁ OAB-āĻāϰ āĻĒā§āϰāϝāĻŧā§‹āϜāύ⧀āϝāĻŧ Urgency symptom āύāĻĨāĻŋāϭ⧁āĻ•ā§āϤ āύ⧇āχāĨ¤

Confidence: 0.99 — Drug identification; 0.74 — Treatment rationale.


7.4 Medicine No. 4 — Sudac 200 mg

1. Generic: Sulindac.

2. Brand: Sudac 200 mg.

3. Alternate Brands: Olida 200 mg, Lindac 200 mg, Clinorel 200 mg.

4. MedEx Therapeutic Class: Drugs for Osteoarthritis; Drugs used for Rheumatoid Arthritis; Drugs used in Gout; NSAIDs.

5. Pharmacological Class: Nonselective NSAID.

6. Purpose: Pain and inflammation relief.

7. Why prescribed: Bilateral shoulder pain āĻāĻŦāĻ‚ Low Back Pain āĻ•āĻŽāĻžāύ⧋āϰ āϜāĻ¨ā§āϝāĨ¤

8. Side Effects: Gastritis, peptic ulcer, GI bleeding, renal injury, edema, hypertension āĻ“ dizzinessāĨ¤

9. MedEx Link: Sudac 200 mg — MedEx

10. Price & Composition: Unit ā§ŗ10; Strip ā§ŗ100āĨ¤ āĻāĻ•āχ brand-āĻ 100 mg āϰāϝāĻŧ⧇āϛ⧇āĨ¤

11. Mechanism: Active sulfide metabolite prostaglandin synthesis āĻ•āĻŽāĻžāϝāĻŧāĨ¤

12. Indications: RA, OA, acute painful shoulder, inflammatory musculoskeletal disorders āĻāĻŦāĻ‚ goutāĨ¤

13. Interactions & Contraindications: Anticoagulants, antiplatelets, āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ NSAIDs, aspirin āĻāĻŦāĻ‚ āĻ•āĻŋāϛ⧁ renal-risk medicines-āĻāϰ āϏāĻ™ā§āϗ⧇ clinically significant interaction āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤ Active GI ulcer/bleeding āĻŦāĻž NSAID allergy-āϤ⧇ contraindicatedāĨ¤

14. Precautions: ā§Žā§Ģ āĻŦāĻ›āϰ āĻŦāϝāĻŧāϏ⧇ GI bleeding, kidney injury āĻāĻŦāĻ‚ fluid retention-āĻāϰ āĻā§āρāĻ•āĻŋ āĻŦ⧇āĻļāĻŋāĨ¤ PPI āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāϞ⧇āĻ“ NSAID-āĻāϰ āϏāĻŦ āĻā§āρāĻ•āĻŋ āĻĻā§‚āϰ āĻšāϝāĻŧ āύāĻžāĨ¤

15. Dosage: Prescription: 200 mg twice daily for 10 days = 400 mg/dayāĨ¤ MedEx-āĻ 400 mg/day āϏāĻ°ā§āĻŦā§‹āĻšā§āϚ āĻŽāĻžāĻ¤ā§āϰāĻž āĻšāĻŋāϏ⧇āĻŦ⧇ āωāĻ˛ā§āϞ⧇āĻ– āφāϛ⧇āĨ¤

16. Pregnancy & Lactation: Late pregnancy-āĻ NSAIDs āĻ•ā§āώāϤāĻŋāĻ•āϰ; breastfeeding-āĻāĻ“ āϏāϤāĻ°ā§āĻ•āϤāĻž āĻĒā§āϰāϝāĻŧā§‹āϜāύāĨ¤ āϰ⧋āĻ—ā§€āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āĻĒā§āϰāϝ⧋āĻœā§āϝ āύāϝāĻŧāĨ¤

Clinical Verdict: āĻŦā§āϝāĻĨāĻž āĻ•āĻŽāĻžāύ⧋āϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ āĻĒāϰāĻŋāĻˇā§āĻ•āĻžāϰāĨ¤ āϤāĻŦ⧇ ā§Žā§Ģ āĻŦāĻ›āϰ āĻŦāϝāĻŧāϏ⧀ āϰ⧋āĻ—ā§€āϰ āϜāĻ¨ā§āϝ maximum listed daily dose āĻŦā§āϝāĻŦāĻšāĻžāϰ āωāĻ˛ā§āϞ⧇āĻ–āϝ⧋āĻ—ā§āϝ safety concernāĨ¤ āĻĻā§āϰ⧁āϤ dose–risk review āĻĒā§āϰāϝāĻŧā§‹āϜāύāĨ¤

Confidence: 0.99 — Dose verification; 0.97 — Geriatric safety concern.


7.5 Medicine No. 5 — Tofatin XR 11 mg

âš ī¸ High-Priority Medication Safety Review

1. Generic: Tofacitinib.

2. Brand: Tofatin XR 11 mg.

3. Alternate Brands: Tofacit XR 11 mg, Tofacinix 11 mg, Xelnib XR 11 mg.

4. MedEx Therapeutic Class: Immunosuppressant.

5. Pharmacological Class: Janus Kinase Inhibitor — JAK inhibitor; targeted synthetic DMARD.

6. Purpose: āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻĒā§āϰāĻĻāĻžāĻšāϜāύāĻŋāϤ Autoimmune Disease-āĻāϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĨ¤

7. Why prescribed: āϰ⧋āĻ—ā§€āϰ āĻ•āĻžāρāϧ⧇āϰ āĻŦā§āϝāĻĨāĻž āĻāĻŦāĻ‚ RA Factor test āĻĻ⧇āϖ⧇ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ inflammatory arthritis-āĻāϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ āĻ…āύ⧁āĻŽāĻžāύ āĻ•āϰāĻž āϝāĻžāϝāĻŧāĨ¤ āĻ•āĻŋāĻ¨ā§āϤ⧁ āĻĒā§‚āĻ°ā§āĻŦ⧇ āύāĻŋāĻļā§āϚāĻŋāϤ RA diagnosis āĻŦāĻž Methotrexate treatment history āĻĒāĻžāĻ“āϝāĻŧāĻž āϝāĻžāϝāĻŧāύāĻŋāĨ¤

8. Side Effects: Serious infection, herpes zoster, blood-count abnormalities, lipid elevation; āĻĒāĻžāĻļāĻžāĻĒāĻžāĻļāĻŋ Major Cardiovascular Events, Malignancy, Thrombosis āĻāĻŦāĻ‚ mortality-related boxed warnings āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖāĨ¤

9. MedEx Link: Tofatin XR 11 mg — MedEx

10. Price & Composition: Unit ā§ŗ80; Strip ā§ŗ800āĨ¤ āĻāĻ•āχ brand-āĻāϰ 5 mg immediate-release tablet āφāϛ⧇āĨ¤

11. Mechanism: JAK–STAT signaling pathway inhibit āĻ•āϰ⧇ inflammatory cytokine signaling āĻ•āĻŽāĻžāϝāĻŧāĨ¤

12. Indications: āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āϰ⧋āĻ—ā§€āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ Rheumatoid Arthritis, Psoriatic Arthritis āĻāĻŦāĻ‚ Ulcerative ColitisāĨ¤

13. Interactions & Contraindications: Strong CYP3A4 inhibitors, CYP3A4 inducers āĻāĻŦāĻ‚ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ immunosuppressive drugs āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖāĨ¤ Serious active infection-āĻ āĻ“āώ⧁āϧāϟāĻŋ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻž āωāϚāĻŋāϤ āύāϝāĻŧāĨ¤

14. Precautions: CBC, LFT, renal function, lipid profile, TB screening, hepatitis screening, vaccination status āĻāĻŦāĻ‚ infection assessment āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖāĨ¤ ā§Ŧā§Ģ āĻŦāĻ›āϰ⧇āϰ āĻŦ⧇āĻļāĻŋ āĻŦāϝāĻŧāϏ⧇ āĻŦāĻŋāĻļ⧇āώ āϏāϤāĻ°ā§āĻ•āϤāĻž āĻĒā§āϰāϝāĻŧā§‹āϜāύāĨ¤

15. Dosage: Prescription: 11 mg XR once at night for 20 daysāĨ¤ āĻāϟāĻŋ RA-āĻāϰ āĻāĻ•āϟāĻŋ āĻ¸ā§āĻŦā§€āĻ•ā§ƒāϤ daily formulation, āĻ•āĻŋāĻ¨ā§āϤ⧁ dose appropriateness āϰ⧋āĻ—, renal function, hepatic function āĻāĻŦāĻ‚ treatment history-āĻāϰ āĻ“āĻĒāϰ āύāĻŋāĻ°ā§āĻ­āϰāĻļā§€āϞāĨ¤

16. Pregnancy & Lactation: Pregnancy-āϤ⧇ fetal risk āĻāĻŦāĻ‚ breastfeeding-āĻ safety concerns āϰāϝāĻŧ⧇āϛ⧇āĨ¤ āĻŦāĻ°ā§āϤāĻŽāĻžāύ āϰ⧋āĻ—ā§€āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āĻĒā§āϰāϝ⧋āĻœā§āϝ āύāϝāĻŧāĨ¤

Clinical Verdict

Tofacitinib āϏāĻžāϧāĻžāϰāĻŖ āĻ•āĻžāρāϧ⧇āϰ āĻŦā§āϝāĻĨāĻžāϰ āĻ“āώ⧁āϧ āύāϝāĻŧāĨ¤ āĻāϟāĻŋ āĻļ⧁āϰ⧁ āĻ•āϰāĻžāϰ āφāϗ⧇ inflammatory arthritis-āĻāϰ diagnosis āĻāĻŦāĻ‚ āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ treatment history āĻĒā§āϰāϤāĻŋāĻˇā§āĻ āĻŋāϤ āĻĨāĻžāĻ•āĻž āĻĻāϰāĻ•āĻžāϰāĨ¤

āĻāχ āϰ⧋āĻ—ā§€āϰ Common Cold āϞ⧇āĻ–āĻž āϰāϝāĻŧ⧇āϛ⧇āĨ¤ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āĻ•āϤāϟāĻž āϗ⧁āϰ⧁āϤāϰ, āφāĻĻ⧌ active infection āφāϛ⧇ āĻ•āĻŋ āύāĻž āĻāĻŦāĻ‚ medication continuation āύāĻŋāϰāĻžāĻĒāĻĻ āĻ•āĻŋ āύāĻž prescribing physician-āϕ⧇ āĻĻā§āϰ⧁āϤ āϝāĻžāϚāĻžāχ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

EULAR-āĻāϰ 2025 RA management update, āϝāĻž 2026 āϏāĻžāϞ⧇ āĻĒā§āϰāĻ•āĻžāĻļāĻŋāϤ āĻšāϝāĻŧ⧇āϛ⧇, JAK inhibitors āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āφāϗ⧇ cardiovascular, malignancy āĻ“ thromboembolic risks āĻŦāĻŋāĻŦ⧇āϚāύāĻžāϰ āĻ“āĻĒāϰ āϗ⧁āϰ⧁āĻ¤ā§āĻŦ āĻĻāĻŋāϝāĻŧ⧇āϛ⧇āĨ¤

Confidence: 0.99 — Safety concerns; 0.34 — Evidence that this patient has RA.


7.6 Medicine No. 6 — Merolin 5 mg

Brand identification: āĻšāĻžāϤ⧇āϰ āϞ⧇āĻ–āĻž āĻĨ⧇āϕ⧇ Merolin 5 mg āϏāĻŦāĻšā§‡āϝāĻŧ⧇ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻĒāĻžāĻ āĨ¤ āĻ“āώ⧁āϧ⧇āϰ āĻĒā§āϝāĻžāϕ⧇āϟ āĻĻāĻŋāϝāĻŧ⧇ āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

1. Generic: Mirogabalin Besylate.

2. Brand: Merolin 5 mg.

3. Alternate Brands: Migalin 5 mg, GabaFix 5 mg, Neumig 5 mg.

4. MedEx Therapeutic Class: Adjunct Anti-epileptic Drugs; Primary Anti-epileptic Drugs.

5. Pharmacological Class: Gabapentinoid; α₂δ calcium-channel ligand.

6. Purpose: Neuropathic Pain āĻ•āĻŽāĻžāύ⧋āĨ¤

7. Why prescribed: Low Back Pain-āĻāϰ āϏāĻ™ā§āϗ⧇ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ Neuropathic Component āϏāĻ¨ā§āĻĻ⧇āĻš āĻ•āϰ⧇ āĻĻ⧇āĻ“āϝāĻŧāĻž āĻšāϝāĻŧ⧇ āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

8. Side Effects: Somnolence, dizziness, edema, weight gain āĻāĻŦāĻ‚ impaired coordinationāĨ¤

9. MedEx Link: Merolin 5 mg — MedEx

10. Price & Composition: Unit ā§ŗ20; Strip ā§ŗ200āĨ¤ āĻāĻ•āχ brand-āĻ 2.5 mg āĻ“ 10 mg āϰāϝāĻŧ⧇āϛ⧇āĨ¤

11. Mechanism: Voltage-Gated Calcium Channel-āĻāϰ α₂δ subunit-āĻāϰ āϏāĻ™ā§āϗ⧇ āϝ⧁āĻ•ā§āϤ āĻšāϝāĻŧ⧇ neurotransmitter release āĻ•āĻŽāĻžāϝāĻŧāĨ¤

12. Indications: Peripheral Neuropathic Pain, Diabetic Peripheral Neuropathy āĻ“ Postherpetic NeuralgiaāĨ¤

13. Interactions & Contraindications: Sedatives, alcohol āĻ“ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ CNS depressants-āĻāϰ āϏāĻ™ā§āϗ⧇ sedation āĻŦāĻžāĻĄāĻŧāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤ Hypersensitivity-āϤ⧇ contraindicatedāĨ¤

14. Precautions: āĻ•āĻŋāĻĄāύāĻŋāϰ āĻ•āĻžāĻ°ā§āϝāĻ•āĻžāϰāĻŋāϤāĻž āĻ…āύ⧁āϝāĻžāϝāĻŧā§€ dose adjustment āĻĒā§āϰāϝāĻŧā§‹āϜāύāĨ¤ ā§Žā§Ģ āĻŦāĻ›āϰ āĻŦāϝāĻŧāϏ⧇ Falls āĻāĻŦāĻ‚ fracture risk āĻŦāĻŋāĻļ⧇āώāĻ­āĻžāĻŦ⧇ āĻŦāĻŋāĻŦ⧇āĻšā§āϝāĨ¤

15. Dosage: Prescription: 5 mg twice daily for 15 daysāĨ¤ MedEx-āĻ āĻāϟāĻŋ āϏāĻžāϧāĻžāϰāĻŖ adult starting dose, āĻ•āĻŋāĻ¨ā§āϤ⧁ renal impairment āĻĨāĻžāĻ•āϞ⧇ āĻ•āĻŽ dose āĻĻāϰāĻ•āĻžāϰ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

16. Pregnancy & Lactation: āĻĒāĻ°ā§āϝāĻžāĻĒā§āϤ human safety evidence āϏ⧀āĻŽāĻŋāϤ; āĻĒā§āϰāϝāĻŧā§‹āϜāύ āĻ…āύ⧁āϝāĻžāϝāĻŧā§€ risk–benefit assessmentāĨ¤ āĻŦāĻ°ā§āϤāĻŽāĻžāύ āϰ⧋āĻ—ā§€āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āĻĒā§āϰāϝ⧋āĻœā§āϝ āύāϝāĻŧāĨ¤

Clinical Verdict: Neuropathic Pain-āĻāϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϝāĻŧ āĻŦā§āϝāĻŦāĻšāĻžāϰ āωāĻĒāϝ⧁āĻ•ā§āϤ āĻšāϤ⧇ āĻĒāĻžāϰ⧇; āĻ•āĻŋāĻ¨ā§āϤ⧁ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ Burning Pain, Tingling, Numbness āĻŦāĻž Radiculopathy āϞ⧇āĻ–āĻž āύ⧇āχāĨ¤

Confidence: 0.83 — Brand identification; 0.43 — Neuropathic indication in this patient.


7.7 Medicine No. 7 — Zo-MUPS 40 mg

1. Generic: Esomeprazole.

2. Brand: Zo-MUPS 40 mg.

3. Alternate Brands: Emep MUPS 40 mg, Sergel MUPS 40 mg.

4. MedEx Therapeutic Class: Proton Pump Inhibitor.

5. Pharmacological Class: PPI.

6. Purpose: Gastric acid suppression.

7. Why prescribed: Sulindac-related upper GI injury risk āĻ•āĻŽāĻžāύ⧋āϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ⧇ āĻ…āĻĨāĻŦāĻž acid-related symptoms-āĻāϰ āϜāĻ¨ā§āϝāĨ¤

8. Side Effects: Headache, diarrhea, abdominal discomfort; āĻĻā§€āĻ°ā§āϘāĻŽā§‡āϝāĻŧāĻžāĻĻ⧇ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āϰ⧋āĻ—ā§€āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ hypomagnesemia, fracture āĻāĻŦāĻ‚ kidney-related complications āĻŦāĻŋāĻŦ⧇āĻšā§āϝāĨ¤

9. MedEx Link: Zo-MUPS 40 mg — MedEx

10. Price & Composition: Unit ā§ŗ17; Strip ā§ŗ170āĨ¤ āĻāĻ•āχ brand-āĻ 20 mg āϰāϝāĻŧ⧇āϛ⧇āĨ¤

11. Mechanism: Gastric Hâē/Kâē-ATPase proton pump inhibit āĻ•āϰ⧇ acid secretion āĻ•āĻŽāĻžāϝāĻŧāĨ¤

12. Indications: GERD, erosive esophagitis, peptic ulcer āĻāĻŦāĻ‚ NSAID-associated ulcer prevention/treatmentāĨ¤

13. Interactions & Contraindications: CYP2C19-related interactions āĻāĻŦāĻ‚ pH-dependent absorption of some drugs āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖāĨ¤ Hypersensitivity-āϤ⧇ contraindicatedāĨ¤

14. Precautions: āĻĻā§€āĻ°ā§āϘāĻŽā§‡āϝāĻŧāĻžāĻĻāĻŋ āĻ…āĻĒā§āϰāϝāĻŧā§‹āϜāύ⧀āϝāĻŧ PPI āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāĻĄāĻŧāĻžāϤ⧇ āĻšāĻŦ⧇āĨ¤ GI protection āĻĨāĻžāĻ•āϞ⧇āĻ“ NSAID-induced bleeding risk āĻĒ⧁āϰ⧋āĻĒ⧁āϰāĻŋ āĻĻā§‚āϰ āĻšāϝāĻŧ āύāĻžāĨ¤

15. Dosage: Prescription: 40 mg twice daily, āĻ–āĻžāĻŦāĻžāϰ⧇āϰ ā§Šā§Ļ āĻŽāĻŋāύāĻŋāϟ āφāϗ⧇, ā§§ā§Ģ āĻĻāĻŋāύāĨ¤ MedEx-āĻ āĻ…āϧāĻŋāĻ•āĻžāĻ‚āĻļ āϏāĻžāϧāĻžāϰāĻŖ GERD/NSAID-protection indication-āĻāϰ āϜāĻ¨ā§āϝ once-daily regimen āϰāϝāĻŧ⧇āϛ⧇; āϤāĻžāχ twice-daily 40 mg-āĻāϰ indication āϝāĻžāϚāĻžāχ āĻ•āϰāĻž āωāϚāĻŋāϤāĨ¤

16. Pregnancy & Lactation: Pregnancy/breastfeeding-āĻ āĻŦā§āϝāĻŦāĻšāĻžāϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ risk–benefit assessment āĻ…āύ⧁āϝāĻžāϝāĻŧā§€āĨ¤

Clinical Verdict: Gastric protection-āĻāϰ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āωāĻĻā§āĻĻ⧇āĻļā§āϝ āϝ⧁āĻ•ā§āϤāĻŋāϏāĻ‚āĻ—āϤ; āĻ•āĻŋāĻ¨ā§āϤ⧁ 80 mg/day āĻāχ āϰ⧋āĻ—ā§€āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āϕ⧇āύ āĻĒā§āϰāϝāĻŧā§‹āϜāύ, āϤāĻž āύāĻĨāĻŋāϭ⧁āĻ•ā§āϤ āύ⧇āχāĨ¤

Confidence: 0.99 — Drug identification; 0.79 — Presumed purpose.


7.8 Medicine No. 8 — Gavirad Suspension

1. Generic: Sodium Alginate + Sodium Bicarbonate + Calcium Carbonate.

2. Brand: Gavirad.

3. Alternate Brands: Gavinil, Gavinor, Gaviplus — āĻāĻ•āχ composition āĻ“ strength āϝāĻžāϚāĻžāχ āϏāĻžāĻĒ⧇āĻ•ā§āώ⧇āĨ¤

4. MedEx Therapeutic Class: Antacids.

5. Pharmacological Class: Alginate-based reflux suppressant and antacid combination.

6. Purpose: Acid Reflux āĻ“ Heartburn-āĻāϰ symptomatic reliefāĨ¤

7. Why prescribed: Gastric discomfort-āĻāϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āĻ…āĻĨāĻŦāĻž NSAID-associated upper GI symptoms āĻ•āĻŽāĻžāύ⧋āϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ⧇ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

8. Side Effects: Constipation, belching, bloating āĻāĻŦāĻ‚ abdominal discomfortāĨ¤

9. MedEx Link: Gavirad — MedEx

10. Price & Composition: 200 mL bottle ā§ŗ300; 10 mL sachet ā§ŗ15āĨ¤ āĻĒā§āϰāϤāĻŋ 10 mL-āĻ Sodium Alginate 500 mg + Sodium Bicarbonate 267 mg + Calcium Carbonate 160 mgāĨ¤

11. Mechanism: Gastric contents-āĻāϰ āĻ“āĻĒāϰ protective alginate raft āϤ⧈āϰāĻŋ āĻ•āϰ⧇ āĻāĻŦāĻ‚ stomach acid neutralize āĻ•āϰ⧇āĨ¤

12. Indications: GERD, Heartburn, IndigestionāĨ¤

13. Interactions & Contraindications: āĻ…āĻ¨ā§āϝ āĻ•āĻŋāϛ⧁ oral medicines-āĻāϰ absorption āĻ•āĻŽāϤ⧇ āĻĒāĻžāϰ⧇; MedEx āĻ…āύ⧁āϝāĻžāϝāĻŧā§€ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻ“āώ⧁āϧ āĻĨ⧇āϕ⧇ āĻĒā§āϰāĻžāϝāĻŧ āĻĻ⧁āχ āϘāĻŖā§āϟāĻž āĻŦā§āϝāĻŦāϧāĻžāύ āĻĒā§āϰāϝāĻŧā§‹āϜāύ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤ Hypersensitivity-āϤ⧇ contraindicatedāĨ¤

14. Precautions: Heart Failure, severe renal disease āĻ…āĻĨāĻŦāĻž sodium-restricted diet āĻĨāĻžāĻ•āϞ⧇ sodium/calcium content āĻŦāĻŋāĻŦ⧇āϚāύāĻž āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

15. Dosage: Prescription: 2 teaspoons three times daily for 15 daysāĨ¤ āĻāĻ•āϟāĻŋ standard 5 mL measuring spoon āϧāϰ⧇ āĻĒā§āϰāϤāĻŋ dose 10 mLāĨ¤ MedEx adult dosage: 10–20 mL after meals and at bedtime, up to four times dailyāĨ¤

16. Pregnancy & Lactation: MedEx āĻ…āύ⧁āϝāĻžāϝāĻŧā§€ clinically necessary āĻšāϞ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻž āϝāĻžāϝāĻŧ; āĻŦāĻ°ā§āϤāĻŽāĻžāύ āϰ⧋āĻ—ā§€āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āĻĒā§āϰāϝ⧋āĻœā§āϝ āύāϝāĻŧāĨ¤

Clinical Verdict: Acid reflux-āĻāϰ symptomatic treatment-āĻāϰ āϏāĻ™ā§āϗ⧇ āϏāĻžāĻŽāĻžā§āϜāĻ¸ā§āϝāĻĒā§‚āĻ°ā§āĻŖ; āϤāĻŦ⧇ āĻŽā§‚āϞ C/C-āϤ⧇ Heartburn āĻŦāĻž Dyspepsia āϞ⧇āĻ–āĻž āύ⧇āχāĨ¤

Confidence: 0.90 — Brand identification; 0.69 — Patient-specific indication.


7.9 Medicine No. 9 — Brofex TS

âš ī¸ Important Dose Discrepancy

1. Generic: Dextromethorphan Polistirex.

2. Brand: Brofex TS.

3. Alternate Brands: MedEx-āĻ āĻāĻ•āχ Extended-Release Polistirex formulation-āĻāϰ āĻ…āĻ¨ā§āϝ brand āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻž āϝāĻžāϝāĻŧāύāĻŋāĨ¤ Immediate-release Dextromethorphan products āϏāϰāĻžāϏāϰāĻŋ interchangeable āύāϝāĻŧāĨ¤

4. MedEx Therapeutic Class: Cough Suppressant.

5. Pharmacological Class: Centrally acting non-opioid antitussive.

6. Purpose: Dry Cough suppression.

7. Why prescribed: Common Cold-āĻāϰ āϏāĻ™ā§āϗ⧇ dry cough āϰāϝāĻŧ⧇āϛ⧇ āĻŦāϞ⧇ āĻ…āύ⧁āĻŽāĻžāύ āĻ•āϰāĻž āϝāĻžāϝāĻŧ, āϝāĻĻāĻŋāĻ“ C/C-āϤ⧇ cough āφāϞāĻžāĻĻāĻžāĻ­āĻžāĻŦ⧇ āϞ⧇āĻ–āĻž āύ⧇āχāĨ¤

8. Side Effects: Dizziness, nausea, confusion; overdose-āĻ agitation, altered consciousness āĻāĻŦāĻ‚ respiratory depression āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

9. MedEx Link: Brofex TS — MedEx

10. Price & Composition: 100 mL bottle ā§ŗ100āĨ¤ Strength: Dextromethorphan equivalent 30 mg/5 mLāĨ¤

11. Mechanism: Medullary cough centre-āĻāϰ āĻ“āĻĒāϰ āĻ•āĻžāϜ āĻ•āϰ⧇ cough reflex āĻ•āĻŽāĻžāϝāĻŧāĨ¤

12. Indications: Acute or chronic dry/unproductive coughāĨ¤

13. Interactions & Contraindications: MAO inhibitors-āĻāϰ āϏāĻ™ā§āϗ⧇ contraindicated; āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ serotonergic medicines-āĻāϰ āϏāĻ™ā§āϗ⧇ serotonin toxicity-āĻāϰ āĻā§āρāĻ•āĻŋ āĻŦāĻŋāĻŦ⧇āĻšā§āϝāĨ¤

14. Precautions: Elderly patients, liver impairment āĻāĻŦāĻ‚ neurological symptoms āĻĨāĻžāĻ•āϞ⧇ āϏāϤāĻ°ā§āĻ•āϤāĻžāĨ¤

15. Dosage: Prescription: 2 teaspoons × 3 times daily for 15 daysāĨ¤

āϝāĻĻāĻŋ āĻĒā§āϰāϤāĻŋ āϚāĻžāĻŽāϚ 5 mL āĻšāϝāĻŧ:

10 mL × 3 = 30 mL/day = 180 mg/dayāĨ¤

āĻ•āĻŋāĻ¨ā§āϤ⧁ MedEx-āĻāϰ Brofex TS Extended-Release Suspension adult dose:

10 mL every 12 hours; maximum 20 mL/24 hours = 120 mg/dayāĨ¤

āĻ…āĻ°ā§āĻĨāĻžā§Ž āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇āϰ āϞāĻŋāĻ–āĻŋāϤ regimen MedEx maximum-āĻāϰ 1.5 āϗ⧁āĻŖāĨ¤

16. Pregnancy & Lactation: Pregnancy āĻ“ breastfeeding-āĻ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āϤāĻĨā§āϝ āϏ⧀āĻŽāĻŋāϤ; āϰ⧋āĻ—ā§€āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āĻĒā§āϰāϝ⧋āĻœā§āϝ āύāϝāĻŧāĨ¤

Clinical Verdict

āĻāχ āĻĄā§‹āϜ prescribing doctor āĻŦāĻž pharmacist āĻĻāĻŋāϝāĻŧ⧇ āĻĒāϰāĻŦāĻ°ā§āϤ⧀ dose-āĻāϰ āφāϗ⧇āχ āϝāĻžāϚāĻžāχ āĻ•āϰāĻž āĻĒā§āϰāϝāĻŧā§‹āϜāύāĨ¤ āĻāϟāĻŋ transcription error, spoon-size misunderstanding āĻ…āĻĨāĻŦāĻž prescribing error āĻ•āĻŋ āύāĻž āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Confidence: 0.99 — MedEx maximum dose; 0.96 — Dose discrepancy, assuming 5 mL teaspoons.


7.10 Medicine No. 10 — Voligel Max 2%

1. Generic: Diclofenac Sodium.

2. Brand: Voligel Max 2% w/w.

3. Alternate Brands: Voltagel DS 2% āĻāĻŦāĻ‚ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ equivalent-strength topical diclofenac formulationsāĨ¤

4. MedEx Therapeutic Class: Drugs for Osteoarthritis; Drugs used for Rheumatoid Arthritis; NSAIDs.

5. Pharmacological Class: Topical NSAID.

6. Purpose: Local pain and inflammation reliefāĨ¤

7. Why prescribed: Bilateral Shoulder Pain āĻāĻŦāĻ‚ Low Back PaināĨ¤

8. Side Effects: Local skin irritation, redness, rash; systemic adverse effects āϤ⧁āϞāύāĻžāĻŽā§‚āϞāĻ• āĻ•āĻŽ āĻšāϞ⧇āĻ“ āĻ…āϏāĻŽā§āĻ­āĻŦ āύāϝāĻŧāĨ¤

9. MedEx Link: Voligel Max 2% — MedEx

10. Price & Composition: 50 g tube ā§ŗ170āĨ¤ āĻāĻ•āχ brand-āĻāϰ 1% topical gel āϰāϝāĻŧ⧇āϛ⧇āĨ¤

11. Mechanism: Cyclooxygenase-mediated prostaglandin synthesis āĻ•āĻŽāĻžāϝāĻŧāĨ¤

12. Indications: Musculoskeletal pain, osteoarthritis-related pain āĻāĻŦāĻ‚ local inflammatory conditionsāĨ¤

13. Interactions & Contraindications: NSAID hypersensitivity; oral NSAID-āĻāϰ āϏāĻ™ā§āϗ⧇ combined exposure āĻāĻŦāĻ‚ anticoagulant use-āĻāϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āϏāϤāĻ°ā§āĻ•āϤāĻžāĨ¤

14. Precautions: Open wound, eyes āĻŦāĻž mucous membranes-āĻ āĻŦā§āϝāĻŦāĻšāĻžāϰ āύāϝāĻŧāĨ¤ āĻŦāĻĄāĻŧ āĻ…āĻ‚āĻļ⧇ āĻ…āϤāĻŋāϰāĻŋāĻ•ā§āϤ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāĻĄāĻŧāĻžāϤ⧇ āĻšāĻŦ⧇āĨ¤

15. Dosage: Doctor āϞāĻŋāϖ⧇āϛ⧇āύ āĻŦā§āϝāĻĨāĻžāϰ āĻ¸ā§āĻĨāĻžāύ⧇ āĻĻāĻŋāύ⧇ āĻĻ⧁āχāĻŦāĻžāϰ āϞāĻžāĻ—āĻžāϤ⧇, āĻŽā§āϝāĻžāϏāĻžāϜ āύāĻž āĻ•āϰāϤ⧇āĨ¤ MedEx-āĻāϰ general diclofenac gel information formulation āĻ…āύ⧁āϝāĻžāϝāĻŧā§€ āĻ­āĻŋāĻ¨ā§āύ āĻšāϤ⧇ āĻĒāĻžāϰ⧇; prescribed frequency āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

16. Pregnancy & Lactation: Pregnancy-āϤ⧇ āĻŦāĻŋāĻļ⧇āώ āϏāϤāĻ°ā§āĻ•āϤāĻž; āĻŦāĻ°ā§āϤāĻŽāĻžāύ āϰ⧋āĻ—ā§€āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āĻĒā§āϰāϝ⧋āĻœā§āϝ āύāϝāĻŧāĨ¤

Clinical Verdict: Localized musculoskeletal pain-āĻāϰ āϜāĻ¨ā§āϝ āωāĻĒāϝ⧁āĻ•ā§āϤ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤ Oral Sulindac-āĻāϰ āϏāĻ™ā§āϗ⧇ systemic NSAID risk āĻĒāĻ°ā§āϝāĻžāϞ⧋āϚāύāĻž āĻ•āϰāĻž āωāϚāĻŋāϤāĨ¤

Confidence: 0.99 — Drug identification; 0.90 — Intended indication.


8. 🟨 My Clinical Working Assessment — Evidence-Based

Provisional Working Diagnosis

Symptomatic Nocturia of Undetermined Etiology, with Suspected Urinary Storage Dysfunction; Rule Out Symptomatic Lower UTI. Associated Bilateral Shoulder Pain and Low Back Pain of Undetermined Etiology; Evaluate for Degenerative and Inflammatory Musculoskeletal Disease.

āĻŦāĻžāĻ‚āϞāĻž

āĻ•āĻžāϰāĻŖ āĻāĻ–āύ⧋ āύāĻŋāĻ°ā§āϧāĻžāϰāĻŋāϤ āύāϝāĻŧ āĻāĻŽāύ āϰāĻžāϤ⧇āϰ āĻĒā§āϰāĻ¸ā§āϰāĻžāĻŦ⧇āϰ āϏāĻŽāĻ¸ā§āϝāĻž; āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻŽā§‚āĻ¤ā§āϰāĻĨāϞāĻŋāϰ āĻĒā§āϰāĻ¸ā§āϰāĻžāĻŦ āϧāϰ⧇ āϰāĻžāĻ–āĻžāϰ āĻ•āĻžāĻ°ā§āϝāĻ•āĻžāϰāĻŋāϤāĻžāϜāύāĻŋāϤ āϏāĻŽāĻ¸ā§āϝāĻžāĨ¤ āĻŽā§‚āĻ¤ā§āϰāύāĻžāϞ⧀āϰ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āφāϛ⧇ āĻ•āĻŋ āύāĻž āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ•āϰ⧇ āĻĻ⧇āĻ–āϤ⧇ āĻšāĻŦ⧇āĨ¤ āĻĒāĻžāĻļāĻžāĻĒāĻžāĻļāĻŋ āωāĻ­āϝāĻŧ āĻ•āĻžāρāϧ āĻ“ āϕ⧋āĻŽāϰ⧇ āĻŦā§āϝāĻĨāĻž, āϝāĻžāϰ āĻ•āĻžāϰāĻŖ āĻāĻ–āύ⧋ āύāĻŋāĻļā§āϚāĻŋāϤ āύāϝāĻŧāĨ¤ āĻ•ā§āώāϝāĻŧāϜāύāĻŋāϤ āĻ“ āĻĒā§āϰāĻĻāĻžāĻšāϜāύāĻŋāϤ āĻŦāĻžāϤāϰ⧋āĻ— āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ āĻ•āϰāĻž āĻĒā§āϰāϝāĻŧā§‹āϜāύāĨ¤

Confidence: 0.89 — Accuracy of the problem-based working assessment, not confirmation of a specific disease.

Differential Diagnosis

Diagnosis Clinical Support Missing Evidence Confidence
Nocturia — cause undetermined Explicit C/C Frequency, volume, diary 0.99
Possible OAB Nocturia; Mirabegron prescribed Urgency and exclusion of other causes 0.56
Possible Symptomatic Lower UTI Nitrofurantoin prescribed Localizing symptoms, urine findings 0.43
Degenerative Musculoskeletal Pain Advanced age, shoulder/LBP Joint and spine examination 0.61
Rheumatoid Arthritis Tofacitinib and RF test Synovitis, RF/Anti-CCP, history 0.25
Polymyalgia Rheumatica Age 85; bilateral shoulder pain Morning stiffness, ESR/CRP, examination 0.35
Neuropathic Pain Mirogabalin prescribed Neuropathic pain features 0.32
Viral URTI Common Cold documented Respiratory history/examination 0.76

Confidence scores are qualitative evidence-support estimates, not validated statistical probabilities.

Clinical reasoning

Most defensible conclusion: Nocturia āĻāĻŦāĻ‚ musculoskeletal pain āύāĻŋāĻļā§āϚāĻŋāϤāĻ­āĻžāĻŦ⧇ āύāĻĨāĻŋāϭ⧁āĻ•ā§āϤāĨ¤ āĻ•āĻŋāĻ¨ā§āϤ⧁ OAB, UTI āĻŦāĻž RA—āϕ⧋āύ⧋āϟāĻŋāχ āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻžāϰ āĻŽāϤ⧋ āϝāĻĨ⧇āĻˇā§āϟ āϤāĻĨā§āϝ āύ⧇āχāĨ¤

Most important missing detail: āϰ⧋āĻ—ā§€āϰ āĻĒā§‚āĻ°ā§āĻŦ⧇ Rheumatoid Arthritis diagnosed āĻ›āĻŋāϞ āĻ•āĻŋ āύāĻž āĻāĻŦāĻ‚ Tofacitinib āφāϗ⧇ āĻĨ⧇āϕ⧇āχ āϚāϞāĻ›āĻŋāϞ āĻ•āĻŋ āύāĻžāĨ¤ āĻāχ āϤāĻĨā§āϝ medication safety āĻ“ diagnosis āĻĻ⧁āϟāĻŋāχ āωāĻ˛ā§āϞ⧇āĻ–āϝ⧋āĻ—ā§āϝāĻ­āĻžāĻŦ⧇ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ āĻ•āϰāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Confidence: 0.96


9. 🟨 Final Diagnostic Interpretation and Doctor–Reviewer Comparison

🟧 A. Doctor’s Explicit Diagnosis

Doctor’s Dx: Not documented in the prescription.

āĻ…āĻ°ā§āĻĨāĻžā§Ž āĻĄāĻžāĻ•ā§āϤāĻžāϰ āϰ⧋āĻ—āύāĻŋāĻ°ā§āĻŖāϝāĻŧ⧇āϰ āϕ⧋āύ⧋ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āύāĻžāĻŽ āϞ⧇āϖ⧇āύāύāĻŋāĨ¤

āϤāĻŦ⧇ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āϧāϰāύ āĻĻ⧇āϖ⧇ āύāĻŋāĻšā§‡āϰ treatment targets āĻ…āύ⧁āĻŽāĻžāύ āĻ•āϰāĻž āϝāĻžāϝāĻŧ:

  • Urinary infection or urinary symptoms
  • Bladder overactivity/spasm
  • Musculoskeletal or inflammatory pain
  • Possible autoimmune inflammatory disease
  • Gastric acid-related symptoms or prevention
  • Dry cough associated with common cold

āĻāϗ⧁āϞ⧋ āĻĄāĻžāĻ•ā§āϤāĻžāϰ⧇āϰ āϞāĻŋāĻ–āĻŋāϤ Diagnosis āύāϝāĻŧāĨ¤

Confidence: 0.99 — No explicit diagnosis; 0.70 — Inferred treatment targets.

🟩 B. My Clinical Working Diagnosis

Nocturia with possible urinary storage dysfunction; UTI to be excluded; bilateral shoulder and lumbar pain with undetermined cause; inflammatory arthritis requires separate evaluation.

Confidence: 0.87 — Appropriate provisional formulation.

🟧 C. Doctor’s Dx vs My Dx — Comparison

Parameter Doctor’s Prescription My Assessment Agreement
Nocturia Explicit complaint Confirmed symptom 🟩 Yes
UTI Nitrofurantoin prescribed Possible, unconfirmed 🟧 Partial
OAB Mirabegron prescribed Possible, not established 🟧 Partial
Shoulder Pain Explicit complaint Confirmed symptom 🟩 Yes
Rheumatoid Arthritis Tofacitinib prescribed; RF ordered Cannot confirm RA 🟧 Uncertain
Neuropathic Pain Mirogabalin likely prescribed Neuropathy not documented 🟧 Uncertain
Common Cold Explicit complaint Probable uncomplicated URTI 🟩 Broadly consistent
Gastric Disease Acid-suppressive treatment No documented GI symptoms 🟧 Uncertain

🟩 Similarities — āĻŽāĻŋāϞ

1. Urinary symptoms āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āĻāĻ•āϟāĻŋ āĻĒā§āϰāϧāĻžāύ āϞāĻ•ā§āĻˇā§āĻ¯â€”āĻāϤ⧇ āĻļāĻ•ā§āϤāĻŋāĻļāĻžāϞ⧀ āĻŽāĻŋāϞ āϰāϝāĻŧ⧇āϛ⧇āĨ¤

2. Shoulder āĻāĻŦāĻ‚ lower-back pain-āĻāϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āĻĻ⧇āĻ“āϝāĻŧāĻž āĻšāϝāĻŧ⧇āĻ›ā§‡â€”āĻāϟāĻŋāĻ“ āωāĻĒāϏāĻ°ā§āϗ⧇āϰ āϏāĻ™ā§āϗ⧇ āϏāĻžāĻŽāĻžā§āϜāĻ¸ā§āϝāĻĒā§‚āĻ°ā§āĻŖāĨ¤

3. Common Cold-āĻāϰ symptomatic management-āĻāϰ āĻšā§‡āĻˇā§āϟāĻž āĻ•āϰāĻž āĻšāϝāĻŧ⧇āϛ⧇āĨ¤

Confidence: 0.94

🟧 Dissimilarities / Uncertainties — āĻ…āĻŽāĻŋāϞ

1. UTI-āϰ āϜāĻ¨ā§āϝ antibiotic āĻĻ⧇āĻ“āϝāĻŧāĻž āĻšāϞ⧇āĻ“ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻžāϰ āĻĒā§āϰāĻŽāĻžāĻŖ āύ⧇āχāĨ¤

2. Tofacitinib āĻāĻ•āϟāĻŋ āĻļāĻ•ā§āϤāĻŋāĻļāĻžāϞ⧀ immunomodulating drug; āĻļ⧁āϧ⧁ shoulder pain āĻ…āĻĨāĻŦāĻž pending RA Factor-āĻāϰ āĻ­āĻŋāĻ¤ā§āϤāĻŋāϤ⧇ āĻāϰ indication āĻĒā§āϰāϤāĻŋāĻˇā§āĻ āĻŋāϤ āĻšāϝāĻŧ āύāĻžāĨ¤

3. Gabapentinoid āĻĻ⧇āĻ“āϝāĻŧāĻž āĻšāϞ⧇āĻ“ Neuropathic Pain-āĻāϰ characteristic features āύāĻĨāĻŋāϭ⧁āĻ•ā§āϤ āύ⧇āχāĨ¤

4. Acid-suppressive treatment āĻĨāĻžāĻ•āϞ⧇āĻ“ GERD āĻŦāĻž Ulcer-āĻāϰ diagnosis āϞ⧇āĻ–āĻž āύ⧇āχāĨ¤

Confidence: 0.97

Diagnostic Conclusion

Doctor’s explicit Dx āĻāĻŦāĻ‚ My Dx-āĻāϰ āϏāϰāĻžāϏāϰāĻŋ similarity percentage āύāĻŋāĻ°ā§āĻŖāϝāĻŧ āĻ•āϰāĻž āϏāĻŽā§āĻ­āĻŦ āύāϝāĻŧ, āĻ•āĻžāϰāĻŖ Doctor’s Dx āϞ⧇āĻ–āĻž āύ⧇āχāĨ¤

āϤāĻŦ⧇ prescribed medicines-āĻāϰ apparent therapeutic goals āĻāĻŦāĻ‚ working assessment-āĻāϰ āĻŽāĻ§ā§āϝ⧇ āφāĻ‚āĻļāĻŋāĻ• āĻŽāĻŋāϞ āϰāϝāĻŧ⧇āϛ⧇āĨ¤

Confidence: 0.99


10. Guideline-Based Management and Treatment Review

āĻāχ āϰ⧋āĻ—ā§€āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āύāϤ⧁āύ āĻ“āώ⧁āϧ āϝ⧋āĻ— āĻ•āϰāĻžāϰ āφāϗ⧇ āĻŦāĻŋāĻĻā§āϝāĻŽāĻžāύ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āύāĻŋāϰāĻžāĻĒāĻ¤ā§āϤāĻž āĻāĻŦāĻ‚ diagnosis āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻž āĻŦ⧇āĻļāĻŋ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖāĨ¤

A. Nocturia / Possible OAB

AUA/SUFU 2024 āĻ…āύ⧁āϝāĻžāϝāĻŧā§€ āĻĒā§āϰāĻĨāĻŽā§‡ History, Physical Examination, Urinalysis, Bladder Diary āĻ“ āĻĒā§āϰāϝāĻŧā§‹āϜāύ āĻ…āύ⧁āϝāĻžāϝāĻŧā§€ PVR assessment āĻ•āϰāĻž āωāϚāĻŋāϤāĨ¤

āϝāĻĻāĻŋ OAB āύāĻŋāĻļā§āϚāĻŋāϤ āĻšāϝāĻŧ, āϤāĻ–āύ Bladder Training, Behavioral Measures āĻāĻŦāĻ‚ āĻĒā§āϰāϝāĻŧā§‹āϜāύāĻŽāϤ⧋ Pharmacotherapy āĻŦāĻŋāĻŦ⧇āϚāύāĻž āĻ•āϰāĻž āϝāĻžāϝāĻŧāĨ¤

Confidence: 0.98

B. Possible UTI

UTI-āϏāĻ‚āĻļā§āϞāĻŋāĻˇā§āϟ āωāĻĒāϏāĻ°ā§āĻ— āĻĨāĻžāĻ•āϞ⧇ appropriate urine testing āĻ“ āĻĒā§āϰāϝāĻŧā§‹āϜāύāĻŽāϤ⧋ culture āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

āĻŦāϝāĻŧāĻ¸ā§āĻ• āϰ⧋āĻ—ā§€āϰ āĻļ⧁āϧ⧁ Nocturia āĻŦāĻž incidental bacteriuria āĻĻ⧇āϖ⧇ antibiotic āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āϏāĻŋāĻĻā§āϧāĻžāĻ¨ā§āϤ āύ⧇āĻ“āϝāĻŧāĻž āωāϚāĻŋāϤ āύāϝāĻŧāĨ¤

Nitrofurantoin āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āφāϗ⧇ renal function āϝāĻžāϚāĻžāχ āϜāϰ⧁āϰāĻŋāĨ¤ NICE guidance āĻ…āύ⧁āϝāĻžāϝāĻŧā§€ eGFR 45 mL/min/1.73m²-āĻāϰ āύāĻŋāĻšā§‡ āϏāĻžāϧāĻžāϰāĻŖāϤ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ…āύ⧁āĻĒāϝ⧁āĻ•ā§āϤ; eGFR 30–44 āĻšāϞ⧇ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻĒāϰāĻŋāĻ¸ā§āĻĨāĻŋāϤāĻŋāϤ⧇ āϏāϤāĻ°ā§āĻ•āϤāĻžāϰ āϏāĻ™ā§āϗ⧇ āĻ¸ā§āĻŦāĻ˛ā§āĻĒāĻŽā§‡āϝāĻŧāĻžāĻĻāĻŋ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻŦāĻŋāĻŦ⧇āϚāĻŋāϤ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Confidence: 0.99

C. Possible Inflammatory Arthritis

Clinical joint examination, inflammatory markers, RA serology āĻāĻŦāĻ‚ āĻĒā§‚āĻ°ā§āĻŦ⧇āϰ diagnosis/treatment history āϝāĻžāϚāĻžāχ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Confirmed RA āĻĨāĻžāĻ•āϞ⧇ disease activity, treatment response āĻāĻŦāĻ‚ comorbidities āĻ…āύ⧁āϝāĻžāϝāĻŧā§€ DMARD āύāĻŋāĻ°ā§āĻŦāĻžāϚāύ āĻ•āϰāĻž āĻšāϝāĻŧāĨ¤

Tofacitinib āĻļ⧁āϰ⧁ āĻŦāĻž āϚāĻžāϞāĻŋāϝāĻŧ⧇ āϝāĻžāĻ“āϝāĻŧāĻžāϰ āϏāĻŋāĻĻā§āϧāĻžāĻ¨ā§āϤ Rheumatologist-āĻāϰ āϏāĻ™ā§āϗ⧇ āϝāĻžāϚāĻžāχ āĻ•āϰāĻž āĻŦāĻŋāĻļ⧇āώāĻ­āĻžāĻŦ⧇ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖāĨ¤

Confidence: 0.98

D. Musculoskeletal Pain

Degenerative, inflammatory āĻ“ neuropathic pain āφāϞāĻžāĻĻāĻž āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Pain treatment āύāĻŋāĻ°ā§āĻŦāĻžāϚāύ āĻ•āϰāϤ⧇ Kidney Function, GI Bleeding Risk, Falls Risk āĻāĻŦāĻ‚ Polypharmacy āĻŦāĻŋāĻŦ⧇āϚāύāĻž āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Confidence: 0.97


11. Bangladesh Prescription Practice — MedEx-Based Drug Options

Table 2: Disease-Specific Medicines Used in Bangladesh

āύāĻŋāĻšā§‡āϰ āϤāĻžāϞāĻŋāĻ•āĻžāϟāĻŋ āϰ⧋āĻ—āĻ­āĻŋāĻ¤ā§āϤāĻŋāĻ• āĻĒā§āϰāϚāϞāĻŋāϤ therapeutic options-āĻāϰ āωāĻĻāĻžāĻšāϰāĻŖāĨ¤ āĻāĻ•āχ āϰ⧋āĻ—ā§€āϰ āϜāĻ¨ā§āϝ āϏāĻŦāϗ⧁āϞ⧋ āĻāĻ•āϏāĻ™ā§āϗ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰāϝ⧋āĻ—ā§āϝ āύāϝāĻŧ āĻāĻŦāĻ‚ āĻāϟāĻŋ āύāϤ⧁āύ Prescription āύāϝāĻŧāĨ¤

Clinical Condition Generic Medicine Example Bangladesh Brand Purpose
Confirmed susceptible Lower UTI Nitrofurantoin Nintoin SR Urinary antibacterial
Confirmed susceptible Lower UTI Fosfomycin Brand/strength must be verified Urinary antibacterial
OAB Mirabegron M-Beg, Betmira ER Reduce urgency/frequency
Bladder Spasm Flavoxate Uroza, Urilax Symptom relief
OAB Solifenacin Brand must be verified Antimuscarinic therapy
Musculoskeletal Pain Paracetamol Napa Analgesic
Local OA Pain Diclofenac Gel Voligel Max Topical anti-inflammatory
Inflammatory Arthritis Methotrexate Methox Conventional DMARD
Selected Established RA Tofacitinib Tofatin XR Targeted synthetic DMARD
Neuropathic Pain Mirogabalin Merolin, Migalin Neuropathic analgesic
GERD Esomeprazole Zo-MUPS Acid suppression
Reflux Symptoms Alginate combination Gavirad Reflux symptom relief
Dry Cough Dextromethorphan Brofex TS Cough suppression

Important: Table-āĻ āĻĨāĻžāĻ•āĻž āĻ•āĻŋāϛ⧁ brand āϏāϰāĻžāϏāϰāĻŋ MedEx-āĻ āϝāĻžāϚāĻžāχ āĻ•āϰāĻž āĻšāϝāĻŧ⧇āϛ⧇; āϝ⧇āϗ⧁āϞ⧋āϰ āĻĒāĻžāĻļ⧇ brand verification āωāĻ˛ā§āϞ⧇āĻ– āφāϛ⧇, āϏ⧇āĻ–āĻžāύ⧇ generic-level therapeutic option āĻĻ⧇āĻ–āĻžāύ⧋ āĻšāϝāĻŧ⧇āϛ⧇, āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ Bangladesh brand āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻž āĻšāϝāĻŧāύāĻŋāĨ¤

Confidence: 0.96 — Broad drug classes; individual patient suitability requires assessment.

Condition-specific prescribing principles

UTI: Antibiotic selection āĻšāĻŦ⧇ syndrome, renal function, organism susceptibility āĻ“ local resistance pattern āĻ…āύ⧁āϝāĻžāϝāĻŧā§€āĨ¤

OAB: Behavioral Therapy āĻĒā§āϰāĻĨāĻŽ āϧāĻžāĻĒ⧇āϰ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ āĻ…āĻ‚āĻļāĨ¤ Pharmacotherapy-āĻāϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ hypertension, urinary retention āĻāĻŦāĻ‚ cognitive risk āĻŦāĻŋāĻŦ⧇āĻšā§āϝāĨ¤

RA: Methotrexate āĻāĻ•āϟāĻŋ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ conventional DMARD; āϤāĻŦ⧇ āĻāϟāĻŋ āϰ⧋āĻ— āύāĻŋāĻļā§āϚāĻŋāϤ āĻšāĻ“āϝāĻŧāĻž, contraindication screening āĻāĻŦāĻ‚ monitoring āĻ›āĻžāĻĄāĻŧāĻž āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻž āϝāĻžāϝāĻŧ āύāĻžāĨ¤ JAK inhibitor āϏāĻŦ RA āϰ⧋āĻ—ā§€āϰ āĻĒā§āϰāĻĨāĻŽ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āύāϝāĻŧāĨ¤

Pain: ā§Žā§Ģ āĻŦāĻ›āϰ āĻŦāϝāĻŧāϏ⧇ āĻĻā§€āĻ°ā§āϘāĻŽā§‡āϝāĻŧāĻžāĻĻāĻŋ systemic NSAID āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤ⧇ safer alternatives āĻāĻŦāĻ‚ nonpharmacological treatment āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖāĨ¤

Confidence: 0.96


12. Important Drug Interactions and Geriatric Safety Analysis

āĻāχ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇āϰ āϏāĻŦāĻšā§‡āϝāĻŧ⧇ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ clinical āϏāĻŽāĻ¸ā§āϝāĻžāϗ⧁āϞ⧋ āύāĻŋāĻšā§‡ āĻĻ⧇āĻ“āϝāĻŧāĻž āĻšāϞ⧋āĨ¤

Drug Combination / Issue Potential Risk Clinical Priority
Brofex TS written dose Possible excessive daily dose 🔴 Immediate verification
Tofacitinib + possible infection Serious infection risk 🔴 High
Tofacitinib at age 85 Infection, MACE, malignancy, thrombosis considerations 🔴 High
Sulindac 400 mg/day GI bleeding and renal injury 🔴 High
Sulindac + topical Diclofenac Additional NSAID exposure 🟠 Moderate
Mirogabalin + Flavoxate Additive dizziness/sedation, falls 🟠 Moderate
Mirabegron + Flavoxate Potential urinary retention risk 🟠 Moderate
Nitrofurantoin + impaired renal function Reduced suitability/efficacy, toxicity 🔴 High
Gavirad + other oral medications Possible reduced absorption 🟠 Moderate
Esomeprazole 40 mg twice daily Indication for high-dose PPI unclear 🟠 Review

Confidence: 0.94

Three major concerns requiring review

1. Brofex TS dose discrepancy: Written regimen appears to exceed the manufacturer’s listed maximum daily amount.

2. Tofacitinib: At age 85, the risk–benefit balance must be reviewed carefully, especially with possible infection and no documented RA history.

3. Sulindac: Prescription reaches the MedEx maximum daily dose in an elderly patient whose renal function and GI risk are unknown.

Confidence: 0.99 — Importance of review.


13. Clinical Action Plan — āϕ⧀āĻ­āĻžāĻŦ⧇ āϰ⧋āĻ—ā§€āϕ⧇ āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ āĻ•āϰāĻŦ⧇āύ

Step 1 — Immediate Medication Reconciliation

āϰ⧋āĻ—ā§€āϰ āϏāĻ™ā§āϗ⧇ āĻŦā§āϝāĻŦāĻšā§ƒāϤ āϏāĻŦ āĻ“āώ⧁āϧ⧇āϰ strip/bottle āύāĻŋāϝāĻŧ⧇ prescription āĻŽāĻŋāϞāĻŋāϝāĻŧ⧇ āĻĻ⧇āĻ–āϤ⧇ āĻšāĻŦ⧇āĨ¤ āĻŦāĻŋāĻļ⧇āώāϤ Brofex TS, Merolin, Tofatin XR āĻāĻŦāĻ‚ Sudac āϝāĻžāϚāĻžāχ āĻ•āϰ⧁āύāĨ¤

Confidence: 0.99

Step 2 — Evaluate for Infection

Fever, Dysuria, Suprapubic Pain, Flank Pain, Hematuria, systemic illness āĻ…āĻĨāĻŦāĻž new confusion āϰāϝāĻŧ⧇āϛ⧇ āĻ•āĻŋ āύāĻž āϝāĻžāϚāĻžāχ āĻ•āϰ⧁āύāĨ¤

Sepsis, acute systemic deterioration āĻŦāĻž suspected pyelonephritis āĻĨāĻžāĻ•āϞ⧇ āϜāϰ⧁āϰāĻŋ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āĻĒā§āϰāϝāĻŧā§‹āϜāύāĨ¤

Confidence: 0.98

Step 3 — Assess Renal Function

Serum Creatinine, eGFR, āĻĒā§āϰāϝāĻŧā§‹āϜāύ⧇ Cockcroft–Gault Creatinine Clearance āĻāĻŦāĻ‚ electrolyte status āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ•āϰ⧁āύāĨ¤

Confidence: 0.99

Step 4 — Assess Urinary Symptoms

Bladder Diary, Urgency, Frequency, Incontinence, nocturnal urine volume āĻ“ PVR āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ āĻ•āϰ⧁āύāĨ¤

Confidence: 0.98

Step 5 — Evaluate Joint Pain

Joint swelling, Morning Stiffness, range of motion, neurological symptoms āĻāĻŦāĻ‚ appropriate inflammatory markers āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ•āϰ⧁āύāĨ¤

Confidence: 0.96

Step 6 — Review High-Risk Drugs

Rheumatologist/Prescriber āĻĻāĻŋāϝāĻŧ⧇ Tofacitinib-āĻāϰ indication āĻāĻŦāĻ‚ Geriatric Medicine/Clinical Pharmacy āĻĻāĻŋāϝāĻŧ⧇ Polypharmacy review āĻ•āϰāĻž āωāϚāĻŋāϤāĨ¤

Confidence: 0.98


14. Specialist Referral — āϕ⧋āύ āĻĄāĻžāĻ•ā§āϤāĻžāϰ⧇āϰ āĻ•āĻžāϛ⧇ āĻĒāĻžāĻ āĻžāĻŦ⧇āύ?

Primary Referral: Medicine Specialist / Geriatric Medicine

Reason: ā§Žā§Ģ āĻŦāĻ›āϰ āĻŦāϝāĻŧāϏ, āĻāĻ•āĻžāϧāĻŋāĻ• āωāĻĒāϏāĻ°ā§āĻ—, Polypharmacy āĻāĻŦāĻ‚ significant drug-safety concernsāĨ¤

Priority: Prompt review, ideally within 24 hours for medication reconciliation; earlier if currently unwell or adverse effects are suspectedāĨ¤

Confidence: 0.97

Urologist

Persistent Nocturia, Urgency, urinary retention, hematuria āĻ…āĻĨāĻŦāĻž abnormal PVR āĻĨāĻžāĻ•āϞ⧇āĨ¤

Confidence: 0.95

Rheumatologist

āφāϗ⧇ āĻĨ⧇āϕ⧇ RA diagnosis āĻĨāĻžāĻ•āϞ⧇, inflammatory synovitis āĻĒāĻžāĻ“āϝāĻŧāĻž āϗ⧇āϞ⧇ āĻ…āĻĨāĻŦāĻž Tofacitinib treatment-āĻāϰ indication āϝāĻžāϚāĻžāχ āĻ•āϰāϤ⧇āĨ¤

Confidence: 0.99

Nephrologist

Significant renal impairment, unexplained renal deterioration āĻ…āĻĨāĻŦāĻž relevant abnormal renal findings āĻĨāĻžāĻ•āϞ⧇āĨ¤

Confidence: 0.96


15. Clinical Diagnosis Note & Illustrative Prescription Demo

A. Specific Provisional Dx Note

āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ Clinical Record-āĻ, āϝāĻĨāĻžāϝāĻĨ āϝāĻžāϚāĻžāχāϝāĻŧ⧇āϰ āĻĒāϰ, āύāĻŋāĻšā§‡āϰ āĻŽāϤ⧋ āĻāĻ•āϟāĻŋ provisional assessment note āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻž āϝ⧇āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Provisional Dx:

1. Symptomatic Nocturia — Etiology Undetermined; R/O OAB, Symptomatic Lower UTI and Nocturnal Polyuria.

āĻŦāĻžāĻ‚āϞāĻž: āϰāĻžāϤ⧇ āĻŦāĻžāϰāĻŦāĻžāϰ āĻĒā§āϰāĻ¸ā§āϰāĻžāĻŦ āĻšāĻ“āϝāĻŧāĻž; āĻ•āĻžāϰāĻŖ āĻ…āύāĻŋāĻ°ā§āϧāĻžāϰāĻŋāϤāĨ¤ āĻ…āϤāĻŋāϏāĻ•ā§āϰāĻŋāϝāĻŧ āĻŽā§‚āĻ¤ā§āϰāĻĨāϞāĻŋ, āĻŽā§‚āĻ¤ā§āϰāύāĻžāϞ⧀āϰ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āĻ“ āϰāĻžāϤ⧇ āĻ…āϤāĻŋāϰāĻŋāĻ•ā§āϤ āĻĒā§āϰāĻ¸ā§āϰāĻžāĻŦ āĻ‰ā§ŽāĻĒāĻžāĻĻāύ āφāϛ⧇ āĻ•āĻŋ āύāĻž āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

2. Bilateral Shoulder Pain with Low Back Pain — Etiology Undetermined; R/O Degenerative/Inflammatory Musculoskeletal Disease.

āĻŦāĻžāĻ‚āϞāĻž: āωāĻ­āϝāĻŧ āĻ•āĻžāρāϧ āĻ“ āϕ⧋āĻŽāϰ⧇āϰ āĻŦā§āϝāĻĨāĻž; āĻ•ā§āώāϝāĻŧāϜāύāĻŋāϤ āĻ…āĻĨāĻŦāĻž āĻĒā§āϰāĻĻāĻžāĻšāϜāύāĻŋāϤ āϰ⧋āϗ⧇āϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻž āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

3. Insomnia, Possibly Secondary to Nocturia/Pain.

āĻŦāĻžāĻ‚āϞāĻž: āĻ…āύāĻŋāĻĻā§āϰāĻž; āĻĒā§āϰāĻ¸ā§āϰāĻžāĻŦ⧇āϰ āϏāĻŽāĻ¸ā§āϝāĻž āĻ…āĻĨāĻŦāĻž āĻŦā§āϝāĻĨāĻžāϰ āϏāĻ™ā§āϗ⧇ āϏāĻŽā§āĻĒāĻ°ā§āĻ• āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

4. Acute Upper Respiratory Symptoms — Possible Viral URTI.

āĻŦāĻžāĻ‚āϞāĻž: āϏāĻžāϧāĻžāϰāĻŖ āϏāĻ°ā§āĻĻāĻŋ-āϜāĻžāϤ⧀āϝāĻŧ āωāĻĒāϏāĻ°ā§āĻ—; āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻ­āĻžāχāϰāĻžāϏāϜāύāĻŋāϤ āϊāĻ°ā§āĻ§ā§āĻŦāĻļā§āĻŦāĻžāϏāύāĻžāϞ⧀āϰ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖāĨ¤

5. Medication Safety Review Required — High-Risk Polypharmacy.

āĻŦāĻžāĻ‚āϞāĻž: āĻāĻ•āĻžāϧāĻŋāĻ• āωāĻšā§āϚāĻā§āρāĻ•āĻŋāϰ āĻ“āώ⧁āϧ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āĻ•āĻžāϰāϪ⧇ āĻ“āώ⧁āϧ⧇āϰ āύāĻŋāϰāĻžāĻĒāĻ¤ā§āϤāĻž āĻĒ⧁āύāĻ°ā§āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ āĻĒā§āϰāϝāĻŧā§‹āϜāύāĨ¤

Confidence: 0.91 — Suitable problem-oriented provisional documentation.

B. Illustrative Clinical Review Prescription

Educational Example Only — Not a Valid Treatment Prescription

Patient: Mrs. Minoty Roy
Age: 85 years
Date: 16 October 2026

C/C: Nocturia, LBP, Bilateral Shoulder Pain, Insomnia, Common Cold.

O/E: BP 110/70 mmHg; Pulse 96/min; SpO₂ 99%.

Provisional Dx: Symptomatic Nocturia, Etiology Undetermined; Musculoskeletal Pain; Possible URTI.

Investigations / Review:

  1. Review available Urine R/M/E, Creatinine/eGFR, RBS and Lower-Abdominal USG.
  2. Urine Culture if clinically suspected symptomatic UTI.
  3. CBC, ESR/CRP and Anti-CCP if inflammatory arthritis is suspected.
  4. PVR, bladder diary and focused musculoskeletal examination.
  5. Review current medication packs and doses before continuing the regimen.
  6. Verify the indication and safety monitoring for Tofacitinib.

Management: No new medicine prescribed in this educational example. Existing treatment requires clinician-led medication reconciliation and dose verification.

Referral: Medicine/Geriatrics; Urology and Rheumatology as indicated.

Follow-up: Prompt medication review and reassessment after available laboratory results.

Confidence: 0.97 — Safety-focused example; not an authorization to prescribe.


16. Overview / Summary & Final Clinical Assessment

Final Working Clinical Assessment

This 85-year-old woman presents with nocturia, bilateral shoulder pain, low back pain, insomnia and common cold symptoms. The available prescription suggests treatment directed toward urinary symptoms, possible UTI, musculoskeletal pain and possible inflammatory arthritis. However, no definitive diagnosis is documented, and the requested investigations have not been supplied.

āĻŦāĻžāĻ‚āϞāĻžāϝāĻŧ Clinical Conclusion

ā§Žā§Ģ āĻŦāĻ›āϰ āĻŦāϝāĻŧāϏ⧀ āĻāχ āϰ⧋āĻ—ā§€āϰ āĻĒā§āϰāϧāĻžāύ āϏāĻŽāĻ¸ā§āϝāĻž āϰāĻžāϤ⧇ āĻŦāĻžāϰāĻŦāĻžāϰ āĻĒā§āϰāĻ¸ā§āϰāĻžāĻŦ āĻšāĻ“āϝāĻŧāĻž, āωāĻ­āϝāĻŧ āĻ•āĻžāρāϧ āĻ“ āϕ⧋āĻŽāϰ⧇āϰ āĻŦā§āϝāĻĨāĻž, āĻ…āύāĻŋāĻĻā§āϰāĻž āĻāĻŦāĻ‚ āϏāĻ°ā§āĻĻāĻŋāĨ¤

āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇āϰ āĻ“āώ⧁āϧ āĻĻ⧇āϖ⧇ āĻŦā§‹āĻāĻž āϝāĻžāϝāĻŧ āĻĄāĻžāĻ•ā§āϤāĻžāϰ āĻĒā§āϰāĻ¸ā§āϰāĻžāĻŦ⧇āϰ āϏāĻŽāĻ¸ā§āϝāĻž, āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āĻāĻŦāĻ‚ āĻĒā§āϰāĻĻāĻžāĻšāϜāύāĻŋāϤ āĻŦā§āϝāĻĨāĻžāϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āĻ•āϰ⧇āϛ⧇āύāĨ¤

āϤāĻŦ⧇ Overactive Bladder, UTI āĻŦāĻž Rheumatoid Arthritis—āϕ⧋āύ⧋āϟāĻŋāχ āĻŦāĻ°ā§āϤāĻŽāĻžāύ⧇ āύāĻŋāĻļā§āϚāĻŋāϤ āĻŦāϞāĻž āϝāĻžāĻŦ⧇ āύāĻžāĨ¤

āĻĒā§āϰāĻĨāĻŽ āĻ•āĻžāϜ āĻšāϞ⧋ āϰ⧋āĻ—ā§€āϰ āĻĒā§āϰāĻ•ā§ƒāϤ āϏāĻŽāĻ¸ā§āϝāĻž āύāĻŋāĻ°ā§āĻŖāϝāĻŧ āĻ•āϰāĻž, āĻ•āĻŋāĻĄāύāĻŋāϰ āĻ•āĻžāĻ°ā§āϝāĻ•āĻžāϰāĻŋāϤāĻž āϝāĻžāϚāĻžāχ āĻ•āϰāĻž āĻāĻŦāĻ‚ āĻ“āώ⧁āϧāϗ⧁āϞ⧋āϰ āύāĻŋāϰāĻžāĻĒāĻ¤ā§āϤāĻž āĻĒ⧁āύāĻ°ā§āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ āĻ•āϰāĻžāĨ¤

Final Confidence Assessment

Clinical Conclusion Confidence
Correct identification of the main documented complaints 0.99
No explicit Doctor’s Dx documented 0.99
Patient requires medication-safety review 0.99
Brofex TS written-dose discrepancy 0.96
Nocturia is a genuine documented problem 0.99
Underlying OAB is possible 0.56
Symptomatic UTI is possible 0.43
Rheumatoid Arthritis is confirmed 0.25 — Not supported
Definitive overall diagnosis can be established from this image alone 0.15 — Not supported

Final Assessment Confidence: 0.89 for the structured provisional assessment, but substantially lower for any individual etiological diagnosis.


17. References — Textbooks, Guidelines & Peer-Reviewed Evidence

A. Standard Medical Textbooks

1. Harrison’s Principles of Internal Medicine. 22nd Edition. McGraw Hill, 2025. Relevant sections: Urinary Tract Infection, Rheumatoid Arthritis, Musculoskeletal Disorders and Geriatric Medicine.

2. Davidson’s Principles and Practice of Medicine. Elsevier. Relevant sections: Renal/Urinary Disorders and Rheumatic Diseases.

3. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th Edition. McGraw Hill, 2022. Relevant sections: Anti-infectives, NSAIDs and Immunomodulatory Pharmacology.

4. Katzung’s Basic & Clinical Pharmacology. 16th Edition. McGraw Hill. Relevant sections: Antimicrobial Agents, Anti-inflammatory Drugs and Immunopharmacology.

5. Robbins & Cotran Pathologic Basis of Disease. Relevant sections: Urinary System and Immune-Mediated Inflammatory Diseases.

Note: āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ chapter/page numbers āĻāĻ–āĻžāύ⧇ primary textbook āĻĨ⧇āϕ⧇ āϏāϰāĻžāϏāϰāĻŋ āϝāĻžāϚāĻžāχ āĻ•āϰāĻž āĻšāϝāĻŧāύāĻŋ; āϤāĻžāχ āĻ…āύ⧁āĻŽāĻžāύ āĻ•āϰ⧇ page number āĻĻ⧇āĻ“āϝāĻŧāĻž āĻšāϝāĻŧāύāĻŋāĨ¤

B. International Clinical Guidelines

6. AUA/SUFU Guideline, 2024: Diagnosis and Treatment of Idiopathic Overactive Bladder.
DOI: 10.1097/JU.0000000000003985.

7. IDSA Clinical Practice Guideline, 2019: Management of Asymptomatic Bacteriuria.
DOI: 10.1093/cid/ciz021.

8. NICE NG109: Urinary Tract Infection (Lower): Antimicrobial Prescribing.
NICE Guideline NG109

9. EULAR Recommendations, 2025 Update (Published 2026): Management of Rheumatoid Arthritis with DMARDs.
DOI: 10.1016/j.ard.2026.01.023.

10. AGS Beers Criteria, 2023: Potentially Inappropriate Medication Use in Older Adults.
DOI: 10.1111/jgs.18372.

11. FDA Drug Safety Communication, 2021: Safety Warnings for JAK Inhibitors Including Tofacitinib.
FDA Safety Communication

C. Peer-Reviewed Research Articles

12. Ytterberg SR, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. New England Journal of Medicine. 2022;386:316–326.
DOI: 10.1056/NEJMoa2109927.

13. Aletaha D, et al. 2010 Rheumatoid Arthritis Classification Criteria. Arthritis & Rheumatism. 2010;62:2569–2581.
DOI: 10.1002/art.27584.

14. Dasgupta B, et al. 2012 Provisional Classification Criteria for Polymyalgia Rheumatica. Arthritis & Rheumatism. 2012.
DOI: 10.1002/art.34356.

D. Bangladesh Drug Reference

15. MedEx Bangladesh: Brand-specific and generic drug monographs for all ten prescription medicines.

āĻĒā§āϰāϤāĻŋāϟāĻŋ āĻ“āώ⧁āϧ⧇āϰ MedEx link āϏāĻ‚āĻļā§āϞāĻŋāĻˇā§āϟ Drug Analysis āĻ…āĻ‚āĻļ⧇ āĻĻ⧇āĻ“āϝāĻŧāĻž āĻšāϝāĻŧ⧇āϛ⧇āĨ¤


âœī¸ Author Information

Author: Md.Rafiqul Islam Lipu
Publication Series: LIPU MED — Clinical Prescription Review
Department: Urology
Proposed Total Case: 1377
Department Code: 23
Proposed Department Case Number: 25
Date: Friday, 16 October 2026
Time: 5:43 PM (Bangladesh Standard Time; time verified during this review)

Article Status: Clinical draft — requiring medication-name confirmation, investigation results and clinician validation before patient-specific treatment recommendations or publication as a final diagnosis.

Final Clinical Note: āĻāχ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇āϰ āϏāĻŦāĻšā§‡āϝāĻŧ⧇ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ āĻŦāĻŋāώāϝāĻŧ āĻļ⧁āϧ⧁ āϰ⧋āĻ— āύāĻŋāĻ°ā§āĻŖāϝāĻŧ āύāϝāĻŧ; ā§Žā§Ģ āĻŦāĻ›āϰ āĻŦāϝāĻŧāϏ⧀ āϰ⧋āĻ—ā§€āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ Brofex TS-āĻāϰ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻ…āϤāĻŋāϰāĻŋāĻ•ā§āϤ āĻĄā§‹āϜ, Tofacitinib-āĻāϰ āωāĻšā§āϚāĻā§āρāĻ•āĻŋāϰ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāĻŦāĻ‚ Sulindac-āĻāϰ renal/GI safety āĻĻā§āϰ⧁āϤ āϝāĻžāϚāĻžāχ āĻ•āϰāĻžāĨ¤ āĻāϗ⧁āϞ⧋ āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ āύāĻž āĻ•āϰ⧇ āϕ⧋āύ⧋ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āϰ⧋āĻ—āϕ⧇ āύāĻŋāĻļā§āϚāĻŋāϤ āĻŦāĻž āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϕ⧇ āϏāĻŽā§āĻĒā§‚āĻ°ā§āĻŖ āύāĻŋāϰāĻžāĻĒāĻĻ āĻŦāϞāĻž āϝāĻžāĻŦ⧇ āύāĻžāĨ¤

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top